4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives

Description

The present invention relates to 4-(quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives, to processes for their preparation and to their use as medicaments, in particular as antiatherosclerotic medicaments.
It is known that increased blood levels of triglycerides (hypertriglyceridaemia) and cholesterol (hypercholesterolaemia) are associated with the origin of atherosclerotic changes to the vascular walls and coronary heart diseases.
There is also a significantly increased risk of the development of coronary heart diseases if these two risk factors occur in combination, which in turn is accompanied by an over-production of apolipoprotein B-100. There is therefore still a great need to provide effective medicaments for combating atherosclerosis and coronary heart diseases.
The compounds 2(R*)- and 2(S*)-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentylacetic acid (S)-phenylglycinolamide are known from the publication EP-344 519.
The present invention relates to 4-(quinolin-2-yl-methoxy)-phenyl-acetic acid amides of the general formula (I), ##STR1## in which A and D are identical or different and
represent hydrogen, cycloalkyl having 3 to 8 carbon atoms, azido, hydroxyl, halogen, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 6 carbon atoms, or a 5- to 6-membered unsaturated or saturated heterocyclic radical having up to 3 heteroatoms from the series consisting of S, N and/or O,
R.sup.1 represents hydrogen or hydroxyl, or represents straight-chain or branched alkyl having up to 4 carbon atoms,
R.sup.2 represents hydrogen, hydroxyl, halogen, straight-chain or branched alkenyl or alkoxy having in each case up to 8 carbon atoms or cycloalkyl having 3 to 14 carbon atoms, or
represents straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by cycloalkyl having 3 to 14 carbon atoms, phenyl or tetrahydropyranyl, which in their turn can be substituted by halogen, or represents the indanyl radical,
or
R.sup.1 and R.sup.2 together with the carbon atom form a saturated carbocyclic ring having 5 to 7 carbon atoms,
or
R.sup.1 and R.sup.2 together represent a double bond radical of the formula ##STR2## wherein a denotes the number 2, 3, 4, 5, or 6,
E represents a radical of the formula ##STR3## in which R.sup.3 denotes phenyl, methyl or a typical amino-protective group,
R.sup.4 and R.sup.4' are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen,
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 4 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which is optionally substituted up to twice in an identical or different manner by halogen, hydroxyl, pyrrolidinyl, morpholino, amino, trifluoromethyl, trifluoromethoxy, cycloalkyl having 3 to 6 carbon atoms or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl, or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by halogen or by straight-chain or branched alkyl having up to 4 carbon atoms, and/or are optionally substituted by a group of the formula --(O).sub.c --SO.sub.2 R.sup.12,
wherein
c denotes the number 0 or 1 and
R.sup.12 denotes straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
b denotes the number 0, 1 or 2.
T denotes a 5- to 7-membered optionally benzo-fused, saturated, partially unsaturated or unsaturated heterocyclic radical having up to 3 heteroatoms from the series consisting of S, N and/or O, wherein both rings are optionally substituted up to three times in an identical or different manner by halogen, hydroxyl, morpholino, amino, cycloalkyl having 3 to 6 carbon atoms, straight-chain or branched alkyl or alkoxy having in each cage up to 6 carbon atoms or phenyl,
V has the abovementioned meaning of L or T or denotes a radical of the formula ##STR4## wherein d denotes the number 1, 2 or 3,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.e --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
R.sup.7 denotes hydrogen, cyano, trifluoromethyl or straight-chain or branched alkenyl or alkyl having up to 7 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 4 carbon atoms, or denotes alkoxy having up to 6 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and
denote hydrogen, phenyl or straight-chain or branched alkyl having up to 4 carbon atoms,
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally Substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 4 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cycloalkyl having 3 to 6 carbon atoms or phenyl, or denote straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl, cycloalkyl having 3 to 6 carbon atoms, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 4 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17
wherein
R.sup.16 and R.sup.17 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 4 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR5## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, a typical amino-protective group or a radical of the formula --SO.sub.2 R.sup.19.
wherein
R.sup.19 denotes straight-chain or branched alkyl having up to 4 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branched alkyl having 2 to 7 carbon atoms, which is substituted one to three tunes in an identical or different manner by hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy,
or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 6 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen and
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 4 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 4 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR6## phenyl which is optionally substituted up to twice in an identical or different manner by halogen, carboxyl or straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, halogen or by straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms,
and salts thereof,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid metahyloxycarbonylmethylamide,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptylacetamide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide being excluded.
The substituted 4-(quinolin-2-yl-methoxy-phenyl)-acetic acid derivatives according to the invention can also be in the form of their salts. Salts with organic or inorganic bases or acids may in general be mentioned here.
Physiologically acceptable salts are preferred in the context of the present invention. Physiologically acceptable salts of the compounds according to the invention can be salts of the substances according to the invention with mineral acids, carboxylic acids or sulphonic acids. Particularly preferred salts are, for example, those with hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulphonic acid, toluenesulphonic acid, benzenesulphonic acid, naphthalenedisulphonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
Physiologically acceptable salts can also be metal salts or ammonium salts of the compounds according to the invention which have a free carboxyl group or a tetrazolyl radical. Particularly preferred salts are, for example sodium potassium, magnesium or calcium salts, as well as ammunonium salts, which are derived from ammonia, or organic amines, such as, for example, ethylamine, di- or triethylamine, di- or triethanolamine, dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
A heterocyclic radical in general is a 5- to 6-membered, saturated, partially unsaturated or unsaturated ring which can contain up to 3 oxygen, sulphur and/or nitrogen atoms as heteroatoms. Preferred rings are 5and 6-membered rings with one oxygen, sulphur and/or up to 2 nitrogen atoms. Rings which are mentioned as preferred are: thienyl, furyl, pyrrolyl, pyrazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazolyl, oxazolyl, imidazolyl, pyrrolidinyl, piperidinyl, piperazinyl.
A 5- to 6-membered saturated heterocyclic radical which can also contain up to 3 oxygen, sulphur and/or nitrogen atoms as heteroatoms is in general piperidyl, morpholinyl, piperazinyl or pyrrolidyl. Morpholinyl is preferred.
A carbocyclic radical in general is a 3- to 7-membered, preferably 5- to 7-membered, saturated hydrocarbon ring. Cyclopentyl, cyclohexyl or cycloheptyl are mentioned as preferred.
A hydroxy-protective group in the context of the abovementioned definition is in general a protective group from the series consisting of: tert-butoxydiphenylsilyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, tert-butyl-dimethylsilyl, tert-butyl-diphenylsilyl, triphenylsilyl, trimethylsilylethoxycarbonyl, benzyl, benzyloxycarbonyl, 2-nitrobenzyl, 4-nitrobenzyl, 2-nitrobenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, tert-butyloxycarbonyl, allyloxycarbonyl, 4-methoxybenzyl, 4-methoxybenzyloxycarbonyl, formyl, acetyl, trichloroacetyl, 2,2,2-trichloroethoxycarbonyl, 2,4-dimethoxymethyl, 2,4-dimethoxybenzyloxycarbonyl, methylthiomethyl, methoxyethoxymethyl, �2-(trimethylsilyl)ethoxy!methyl, 2-(methylthiomethoxy)ethoxycarbonyl, benzoyl, 4-methylbenzoyl, 4-nitrobenzoyl, 4-fluorobenzoyl, 4-chlorobenzoyl or 4-methoxybenzoyl. Acetyl, benzoyl, benzoyl, or methylbenzyl are preferred.
Amino-protective groups in the context of the invention are the customary amino-protective groups used in peptide chemistry.
These include, preferably: benzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 3,5-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 2-nitro-4,5-dimethoxybenzyloxycarbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, allyloxycarbonyl, vinyloxycarbonyl, 2-nitrobenzyloxycarbonyl, 3,4,5-trimethoxylbenzyloxycarbonyl, cyclohexoxycarbonyl, 1,1-dimethylethoxycarbonyl, adamantylcarbonyl, phthaloyl, 2,2,2-trichloroethoxycarbonyl, 2,,2,2-trichloro-tert-butoxycarbonyl, methyloxycarbonyl, phenoxycarbonyl, 4-nitrophenoxycarbonyl, fluorenyl-9-methoxycarbonyl, formyl, acetyl, propionyl, pivaloyl, 2-chloroacetyl, 2-bromoacetyl, 2,2,2-trifluoroacetyl, 2,2,2-trichloroacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, 4-nitrobenzoyl, phthalimido, isovaleroyl or benzyloxymethylene, 4-nitrobenzyl, 2,4-dinitrobenzyl or 4-nitrophenyl.
The compounds according to the invention can exist in stereoisomeric forms which either behave as mirror images (enantiomers) or do not behave as mirror images (diastereomers). The invention relates to both the enantiomers or diastereomers or the particular mixtures thereof. These mixtures of the enantiomers and diastereomers can be separated into the stereoisomerically uniform constituents in a known manner.
Diastereomers can be represented, for example, by the following formulae: ##STR7##
Preferred compounds of the general formula (I)
are those in which
A and D are identical or different and represent hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, azido, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 5 carbon atoms, pyrryl or imidazolyl,
R.sup.1 represents hydrogen or hydroxyl or represents straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.2 represents hydrogen, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkenyl or alkoxy having in each case up to 7 carbon atoms, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl or cyclododecyl, or
represents straight-chain or branched alkyl having up to 7 carbon atoms, which is optionally substituted by cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl or cycloclodecyl, phenyl or tetrahydropyranyl, which in their turn can be substituted by fluorine, chlorine or bromine, or represents the indanyl radical,
or
R.sup.1 and R.sup.2 together with the carbon atom form a cyclopentyl, cyclohexyl or cycloheptyl ring,
or
R.sup.1 and R.sup. 2 together represent a double bond radical of the formula ##STR8## wherein a denotes the number 2, 3, 4 or 5,
E represents a radical of the formula ##STR9## in which R.sup.3 denotes phenyl, methyl, acetyl or tert-butoxycarbonyl (Boc),
R.sup.4 and R.sup.4' are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen.
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 3 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which are optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, iodine, hydroxyl, pyrrolidinyl, morpholino, amino, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine or by straight-chain or branched alkyl having up to 3 carbon atoms,
and/or are optionally substituted by a group of the formula --(O).sub.c SO.sub.2 --R.sup.12,
wherein
c denotes the number 0 or 1,
and
R.sup.12 denotes straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
b denotes the number 0 or 1,
T denotes a heterocyclic radical of the formula ##STR10## wherein R.sup.25 and R.sup.26 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or amino,
V has the abovementioned meaning of L or T or denotes a radical of the formula ##STR11## wherein d denotes the number 1 or 2,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.d --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
R.sup.7 denotes hydrogen, cyano, trifluoromethyl, vinyl or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 3 carbon atoms, or denotes alkoxy having up to 5 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 3 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cyclopropyl, cyclopentyl cyclohexyl or phenyl, or denote straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by phenyl, cyclopropyl, cyclopentyl, cyclohexyl, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 3 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17,
wherein
R.sup.16 and R.sup.17 identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR12## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, tert-butoxycarbonyl or a radical of the formula --SO.sub.2 R.sup.19,
wherein
R.sup.19 denotes straight-chain or branched alkyl having up to 3 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branch alkyl having 2 to 7 carbon atoms, which is substituted 1 to 3 times in an identical or different manner by _ hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy, or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 5 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen,
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 3 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 3 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR13## phenyl, which is optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, fluorine, chlorine, bromine or by straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
and salts thereof,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid methyloxycarbonyl-methylamide,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptylacetamide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide being excluded.
Particularly preferred compounds of the general formula (I) are those
in which
A and D are identical or different and
represent hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, azido, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 4 carbon atoms, imidazolyl or pyrryl,
R.sup.1 represents hydrogen, hydroxyl or straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.2 represents hydrogen, hydroxyl, fluorine, chlorine, straight-chain or branched alkenyl or alkoxy having in each case up to 5 carbon atoms, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl or cycloundecyl or represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cycloundecyl, phenyl or tetrahydropyranyl, which in their turn can be substituted by fluorine, chlorine or bromine, or represents the indanyl radical,
R.sup.1 and R.sup.2 together with the carbon atom form a cyclopentyl, cyclohexyl or cycloheptyl ring,
E represents a radical of the formula ##STR14## in which R.sup.3 denotes phenyl, methyl, acetyl or tert-butoxycarbonyl (Boc),
R.sup.4 and R.sup.4' are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen,
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 3 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which are optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, iodine, hydroxyl, pyrrolidinyl, morpholino, trifluoromethoxy, trifluoromethyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl, or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by fluorine, chlorine or by straight-chain or branched alkyl having up to 3 carbon atoms,
and/or are optionally substituted by a group of the formula --(O).sub.c SO.sub.2 --R.sup.12,
wherein
c denotes the number 0 or 1,
and
R.sup.12 denotes straight-chain or branched alkyl having up to 3 carbon atoms or phenyl,
b denotes the number 0 or 1,
T denotes a heterocyclic radical of the formula ##STR15## wherein R.sup.25 and R.sup.26 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or amino,
V has the abovementioned meaning of L or T or denotes a radical of the formula ##STR16## wherein d denotes the number 1 or 2,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.d --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
wherein
R.sup.7 denotes hydrogen, cyano, trifluoromethyl, vinyl or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 3 carbon atoms, or denotes alkoxy having up to 3 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15,
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and
denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atom
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 3 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cyclopropyl, cyclopentyl, cyclohexyl or phenyl, or denote straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by phenyl, cyclopropyl, cyclopentyl cyclohexyl, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 3 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17,
wherein
R.sup.16 and R.sup.17 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR17## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, tert-butoxycarbonyl or a radical of the formula --SO.sub.2 R.sup.19,
w.herein
R.sup.19 denotes straight-chain or branched alkyl having up to 3 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branched alkyl having 2 to 7 carbon atoms, which is substituted 1 to 3 times in an identical or different manner by hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy, or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 4 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen,
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 3 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 3 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR18## phenyl, which is optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, fluorine, chlorine, bromine or by straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms.
and salts thereof,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid methyloxycarbonylmethylamide,
2-�4(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptylacetamide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide being excluded.
Processes have also been found for the preparation of the compounds of the general formula (I) according to the invention, characterized in that
�A! in the case where E does not represent the radical of the formula ##STR19## carboxylic acids of the general formula (II) ##STR20## in which A, D, R.sup.1 and R.sup.2 have the meaning given,
if appropriate with prior activation of the carboxylic acid function, are reacted with glycinols or esters thereof of the general formula (III) ##STR21## in which R.sup.27 has the abovementioned scope of meaning of L, V, W and R.sup.8
and
R.sup.28 represents --CH.sub.2 --OH or represents (C.sub.1 -C.sub.8)-alkoxycarbonyl
in inert solvents, in the presence of a base and if appropriate of an auxiliary,
and
�B! in the case where E represents the radical of the group ##STR22## the carboxylic acids of the general formula (II), after prior activation of the carboxylic acid function, are reacted with compounds of the general formula (IV) ##STR23## in which X and L have the abovementioned meaning and
R.sup.29 and R.sup.30 are identical or different and denote C.sub.1 -C.sub.6 -alkyl,
in inert solvents, if appropriate in the presence of a base and/or auxiliary,
and in the case where Y.dbd.CHO, oxidation follows,
and, depending on the particular definition of the abovementioned substituent E, if appropriate an acylation, reduction, hydrolysis, amidation, alkylation, sulphoamidation and/or elimination is carried out by customary methods.
The process according to the invention can be illustrated by way of example by the following equation: ##STR24##
Suitable solvents here are inert organic solvents which do not change under the reaction conditions. These include ethers, such as diethyl ether or tetrahydrofuran, halogenated hydrocarbons, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane, trichloroethane, tetachloroethane, 1,2-dichloroethane or trichloroethylene, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitromethane, dimethylformamide, acetone, acetonitrile or hexamethylphosphoric acid triamide. It is also possible to employ mixtures of the solvents. Methylene chloride, tetrahydrofuran, acetone or dimethylformamide are particularly preferred.
Suitable bases are the customary inorganic or organic bases. These include, preferably, alkali metal hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate, or alkali metal alcoholates such as, for example, sodium ethanolate or potassium ethanolate or sodium methanolate or potassium methanolate, or organic amines, such as triethylamine, picoline or N-methylpiperidine, or amides, such as sodium amide or lithium diisopropylamide, or organometallic compounds, such as butyllithium or phenyllithium. Sodium carbonate and potassium carbonate and triethylamine are preferred.
The base is employed in an amount of 0.6 mol to 5 mol, preferably 0.7 mol to 2 mol, per mole of the compound of the general formula (II).
The reaction is in general carried out in a temperature range from 0.degree. C. to 150.degree. C., preferably from +20.degree. C. to +110.degree. C.
The reaction can be carried out under normal, increased or reduced pressure (for example 0.5 to 5 bar). It is in general carried out under normal pressure.
Compounds which are suitable for activation of the carboxylic acid function are in general bases and/or dehydrating reagents, such as, for example, diisopropylcarbodiimide, dicyclohexylcarbodiimide or N-(3-dimethylammopropyl)-N'-ethylcarbodiimide hydrochloride, or carbonyl compounds, such as carbonyldiimidazole, or 1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium 3-sulphonate, or propanephosphoric acid anhydride or isobutyl chloroformate or benzotriazolyloxy-tris-(dimethylamino)phosphonium hexafluorophosphate or phosphonic acid diphenyl ester amide or methanesulphonyl chloride, if appropriate in the presence of bases, such as triethylamine or N-ethylmorpholine or N-methylpiperidine or dicyclohexylcarbodiimide and N-hydroxysuccinimide.
The acid-binding agents and dehydrating reagents are in general employed in an amount of 0.5 to 3 mol, preferably 1 to 1.5 mol, per mole of the corresponding carboxylic acids.
The carboxylic acid function is in general activated in a temperature range from 0.degree. C. to 150.degree. C., preferably from 0.degree. C. to 80.degree. C., end if appropriate under an inert gas atmosphere.
The alkylation is in general carried out with alkylating agents, such as, for example, (C.sub.1 -C.sub.8)-alkyl halides, sulphonic acid esters or substituted or unsubstituted (C.sub.1 -C.sub.8)-dialkyl- or (C.sub.1 -C.sub.8)-diarylsulphonates, preferably methyl iodide or dimethyl sulphate.
The alkylation is in general carried out in one of the abovementioned solvents, preferably in dimethylformamide, in a temperature range from 0.degree. C. to +70.degree. C., preferably from 0.degree. C. to +30.degree. C., under normal pressure.
Suitable bases for the hydrolysis are the customary inorganic bases. These include, preferably, alkali metal hydroxides or alkaline earth metal hydroxides, such as, for example, sodium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate or sodium bicarbonate, or alkali metal alcoholates, such as sodium methanolate, sodium ethanolate, potassium methanolate, potassium ethanolate or potassium tert-butanolate. Sodium hydroxide or potassium hydroxide are particularly preferably employed.
Suitable solvents for the hydrolysis are water or the organic solvents customary for a hydrolysis. These include, preferably, alcohols, such as methanol, ethanol, propanol, isopropanol or butanol, or ethers, such as tetrahydrofuran or dioxane, or dimethylformamide, or dimethyl sulphoxide. Alcohols, such as methanol, ethanol, propanol or isopropanol, are particularly preferably used. It is also possible to employ mixtures of the solvents mentioned.
If appropriate, the hydrolysis can also be carried out with acids, such as, for example, trifluoroacetic acid, acetic acid, hydrochloric acid, hydrobromic acid, methanesulphonic acid, sulphuric acid or perchloric acid, preferably with trifluoroacetic acid.
The hydrolysis is in general carried out in a temperature range from 0.degree. C. to +100.degree. C., preferably from +20.degree. C. to +80.degree. C.
The hydrolysis is in general carried out under normal pressure. However, it is also possible to carry out the hydrolysis under reduced pressure or finder increased pressure (for example from 0.5 to 5 bar).
In carrying out the hydrolysis, the base is in general employed in an amount of 1 to 3 mol, preferably 1 to 1.5 mol, per mole of the ester. Molar amounts of the reactants are particularly preferably used.
The hydrolysis of tert-butyl esters is in general carried out with acids, such as, for example, hydrochloric acid or trifluoroacetic acid, in the presence of one of the abovementioned solvents and/or water or mixtures thereof, preferably with dioxane or tetrahydrofuran.
The oxidation in the case where Y.dbd.CHO is in general carried out in one of the abovementioned ethers, preferably dioxane, and in the presence of an acid. Acids include, preferably, inorganic acids, such as, for example, hydrochloric acid or sulphuric acid, or organic carboxylic acids having 1-6 C atoms, optionally substituted by fluorine, chlorine and/or bromine, such as, for example, acetic acid, trifluoroacetic acid, trichloroacetic acid or propionic acid, or sulphonic acids with C.sub.1 -C.sub.4 -alkyl radicals or aryl radicals, such as, for example, methanesulphonic acid, ethanesulphonic acid, benzenesulphonic acid or toluenesulphonic acid. Hydrochloric acid is preferred.
The oxidation is in general carried out in a temperature range from 0.degree. C. to +100.degree. C., preferably from +20.degree. C. to +80.degree. C.
The oxidation is in general carried out under normal pressure. However, it is also possible to carry out the oxidation under reduced pressure or under increased pressure (for example from 0.5 to 5 bar).
The amidation and the sulphonamidation are in general carried out in one of the abovementioned solvents, preferably in tetrahydrofuran or methylene chloride.
If appropriate, the amidation and the sulphonamidation can proceed via the activated state of the acid halides, which can be prepared from the corresponding acids by reaction with thionyl chloride, phosphorus trichloride, phosphorus pentachloride, phosphorus tribromide or oxalyl chloride.
The amidation and the sulphonamidation are in general carried out in a temperature range from -20.degree. C. to +80.degree. C., preferably from -10.degree. C. to +30.degree. C., under normal pressure.
Suitable bases for this are, in addition to the abovementioned bases, preferably triethylamine and/or dimethylaminopyridine, DBU or DABCO.
The base is employed in an amount of 0.5 mol to 10 mol, preferably 1 mol to 2 mol, per mole of the corresponding acid or ester.
Acid-binding agents which can be employed for the sulphonamidation are alkali metal or alkaline earth metal carbonates, such as sodium carbonate or potassium carbonate, alkali metal or alkaline earth metal hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, or organic bases, such as pyridine, triethylamine, N-methylpiperidine or bicyclic amidines, such as 1,5-diazabicyclo�3.4.0!-non-5-ene (DBN) or 1,5-diazabicyclo�3.4.0!-undec-5-ene (DBU). Potassium carbonate is preferred.
Suitable dehydrating reagents are carbodiimides, such as, for example, diisopropylcarbodiimide, dicyclohexylcarbodiimide or N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride or carbonyl compounds, such as carbonyldiimidazole, or 1,2-oxazolium compounds, such as 2-ethyl-5-phenyl-1,2-oxazolium-3-sulphonate or propanephosphoric acid anhydride or isobutylchloroformate or benzotriazolyloxy-tris-(dimethylamino)phosphonium hexafluorophosphate or phosphonic acid diphenyl ester-amide or methanesulphonyl chloride, if appropriate in the presence of bases, such as triethylamine or N-ethylmorpholine or N-methylpiperidine or dicyclohexylcarbodiimide or N-hydroxysuccinimide.
The acid-binding agents and dehydrating reagents are in general employed in an amount of 0.5 to 3 mol, preferably 1 to 1.5 mol, per mole of the corresponding carboxylic acids.
Suitable solvents here are all the inert solvents which do not change under the reaction conditions. These include, preferably, alcohols, such as methanol, ethanol, propanol or isopropanol, or ethers, such as diethylene glycol dimethyl ether, or amides, such as hexamethylphosphoric acid triamide or dimethylformamide, or acetic acid. It is also possible to use mixtures of the solvents mentioned.
The reductions can in general be carried out by hydrogen in water or in inert organic solvents, such as alcohols, ethers or halogenated hydrocarbons, or mixtures thereof, with catalysts, such as Raney nickel, palladium, palladium-on-animal charcoal or platinum, or with hydrides or boranes in inert solvents, if appropriate in the presence of a catalyst.
The reaction is preferably carried out with hydrides, such as complex borohydrides or aluminium hydrides. Sodium borohydride, lithium aluminium hydride or sodium cyanoborohydride are particularly preferably employed here.
The reaction is in general carried out in a temperature range from 0.degree. C. to 150.degree. C., preferably from +20.degree. C. to +110.degree. C.
The reaction can be carried out under normal, increased or reduced pressure (for example 0.5 to 5 bar). The reaction is in general carried out under normal pressure.
The acylation is in general carried out in one of the abovementioned solvents, preferably methylene chloride, and in the presence of a typical acylating agent such as, for example, acetyl chloride.
The acylation is in general carried out in a temperature range from 0.degree. C. to 150.degree. C., preferably from +20.degree. C. to +110.degree. C.
The acylation can be carried out under normal, increased or reduced pressure (for example 0.5 to 5 bar). It is in general carried out under normal pressure.
The elimination is in general carried out in one of the abovementioned solvents, in the presence of a base and an auxiliary. Diethylformamide, methyl chloride and triethylamine are preferred.
The elimination is in general carried out in a temperature range from 0.degree. C. to 150.degree. C., preferably from +20.degree. C. to +110.degree. C.
The elimination can be carried out under normal, increased or reduced pressure (for example 0.5 to 5 bar). The elimination is in general carried out under normal pressure.
The compounds of the general formula (II) are known (cf. U.S. Pat. Nos. 4,929,629, 4,970,215, 5,091,392, 5,126,354, EP 414 078, 529 450) or they can be prepared by a process in which
compounds of the general formula (V) ##STR25## in which A, D, R.sup.1 and R.sup.2 have the abovementioned meaning
R.sup.31 represents a typical hydroxy-protective group, preferably benzyl or tert-butyl,
and
R.sup.32 represents hydrogen or represents (C.sub.1 -C.sub.4)-alkyl,
after this protective group has been split off by customary methods, are reacted with compounds of the general formula (VI) ##STR26## in which R.sup.33 represents halogen, preferably bromine,
in inert solvents, if appropriate in the presence of a base,
and in the case of the acids the esters are hydrolysed.
Solvents for the etherification can be inert organic solvents which do not change under the reaction conditions. These include, preferably, ethers, such as, for example, dioxane, tetrahydrofuran or diethyl ether, halogenated hydrocarbons, such as methylene chloride, chloroform, carbon tetrachloride, 1,2-dichloroethane or trichloroethylene, hydrocarbons, such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, nitromethane, dimethylformamide, acetonitrile, acetone or hexamethylphosphoric acid triamide. It is also possible to employ mixtures of these solvents.
Bases which can be employed for the etherification are inorganic or organic bases. These include, preferably, alkali metal hydroxides, such as, for example, sodium hydroxide or potassium hydroxide, alkaline earth metal hydroxide, such as, for example, barium hydroxide, alkali metal carbonates, such as sodium carbonate or potassium carbonate, alkaline earth metal carbonates, such as calcium carbonate, or organic amines (trialkyl(C.sub.1 -C.sub.6)-amines), such as triethylamine, or heterocyclic bases, such as pyridine, methylpiperidine, piperidine or morpholine.
It is also possible to employ alkali metals, such as sodium, and hydrides thereof, such as sodium hydride, as bases.
The etherification is in general carried out in a temperature range from 0.degree. C. to +150.degree. C., preferably from +10.degree. C. to +100.degree. C.
The etherification is in general carried out under normal pressure. However, it is also possible to carry out the process under reduced pressure or increased pressure (for example in a range from 0.5 to 5 bar).
In general, 0.5 to 5, preferably 1 to 2, mol of halide are employed per mole of the reaction partner. The base is in general employed in an amount of 0.5 to 5 mol, preferably 1 to 3 mol, based on the halide.
The hydrolysis of the carboxylic acid esters is carried out by customary methods, by treating the esters with customary bases in inert solvents.
Suitable bases for the hydrolysis are the customary inorganic bases. These include, preferably, alkali metal hydroxides or alkaline earth metal hydroxides, such as, for example, sodium hydroxide, potassium hydroxide or barium hydroxide, or alkali metal carbonates, such as sodium carbonate or potassium carbonate or sodium bicarbonate. Sodium hydroxide or potassium hydroxide are particularly preferably employed.
Suitable solvents for the hydrolysis are water or the organic solvents customary for a hydrolysis. They include, preferably, alcohols, such as methanol, ethanol, propanol, isopropanol or butanol, or ethers, such as tetrahydrofuran or dioxane, or dimethylformamide or dimethyl sulphoxide. Alcohols, such as methanol, ethanol, propanol or isopropanol, are particularly preferably used. It is also possible to employ mixtures of the solvents mentioned.
In general the hydrolysis is carried out in a temperature range from 0.degree. C. to +100.degree. C., preferably from +20.degree. C. to +80.degree. C.
The hydrolysis is in general carried out under normal pressure. However, it is also possible to carry out the hydrolysis under reduced pressure or under increased pressure (for example from 0.5 to 5 bar).
In carrying out the hydrolysis, the base is in general employed in an amount of 1 to 3 mol, preferably 1 to 1.5 mol, per mole of the ester. Molar amounts of the reactants are particularly preferably used.
The compounds of the general formula (III) and (IV) are known.
The compounds of the general formulae (V) and (VI) are known.
The compounds of the general formula (I) according to the invention have an unforeseeable pharmacological action spectrum.
They can be used as active compounds in medicaments for reducing changes to vascular walls and for treatment of coronary heart diseases, cardiac insufficiency, disturbances in cerebral performance, ischaemic cerebral diseases, apoplexy, circulatory disturbances, disturbances in microcirculation and thromboses.
The proliferation of smooth muscle cells also plays a decisive role in the occlusion of vessels. The compounds according to the invention are capable of inhibiting this proliferation and therefore of preventing atherosclerotic processes.
The compounds according to the invention are distinguished by a reduction in the ApoB-100 associated lipoproteins (VLDL and its breakdown products, such as, for example, LDL), of ApoB-100 of triglycerides and of cholesterol. They therefore have valuable pharmacological properties which are superior compared with the prior art.
Surprisingly, the action of the compounds according to the invention comprises initially a reduction or complete inhibition of the formation and/or release of ApoB-100-associated lipoproteins from liver cells, which results in a reduction of the plasma VLDL level. This action in VLDL must be accompanied by a reduction in the plasma level of ApoB-100, LDL, triglycerides and cholesterol; several of the abovementioned risk factors which participate in changes to vascular walls are thus reduced at the same time.
The compounds according to the invention can therefore be employed for prevention and treatment of atherosclerosis, obesity, pancreatitis and constipation.
The invention also relates to a combination of oxyphenyl (phenyl)glycinol amides containing heterocyclic substituents of the general formula (I) with a glucosidase and/or amylase inhibitor for the treatment of familial hyperlipidemia, obesity (adipositas) and diabetes mellitus. Glucosidase and/or amylase inhibitors in the context of the invention are for example Acarbose, Adiposine, Voglibose (AQ-128), Miglitol, Emiglitate, MDL-25637, Camiglibose (MDL-73945), Tendamistate, A1-3688, Treslatin, Pradimicin-Q and Salboslatin. A combination of Acarbose, Miglitol, Emiglitate or Voglibose with one of the abovementioned compounds of the general formula (I) is preferred.
I. Inhibition of the release of ApoB-100-associated lipoproteins
The test for detection of the inhibition of the release of ApoB-100-associated lipoproteins from liver cells was carried out in vitro with cultured liver cells, preferably with cells of the human line HepG2. These cells are grown under standard conditions in a medium for culture of eukaryotic cells, preferably in RPMI 1640, with 10% of foetal calf serum. HepG2 cells synthesize and secrete into the culture supernatant ApoB-100-associated lipoprotein particles, which in principle are built up in a similar manner to the VLDL and LDL particles which are to be found in the plasma.
These particles can be detected with an immunoassay for human LDL. This immunoassay is carried out with antibodies which have been induced against human LDL in the rabbit under standard conditions. The anti-LDL antibodies (rab-anti-LDL-ab) were purified by affinity chromatography on an immunosorbent with human LDL. These purified rab-anti-LDL-ab are adsorbed onto the surface of plastic. This adsorption is expediently carried out on the plastic surface of microtiter plates having 96 wells, preferably on MaxiSorp plates (Nunc). If ApoB-100-associated particles are present in the supernatant of HepG2 cells, these can bind to the insolubilized rab-anti-LDL-ab, and an immune complex which is bonded to the plastic surface is formed. Non-bonded proteins are removed by washing. The immune complex on the plastic surface is detected with monoclonal antibodies, which had been induced against human LDL according to standard conditions and purified. These antibodies were conjugated with the enzyme peroxidase (Boehringer, Mannheim). Peroxidase converts the colourless substrate TMB (Kirkegaard and Perry) into a coloured product in the presence of H.sub.2 O.sub.2. After acidification of the reaction mixture with H.sub.2 SO.sub.4, the specific light adsorption at 450 nm, which is a measure of the amount of ApoB-100-associated particles which had been secreted into the culture supernatant by the HepG2 cells, is determined.
Surprisingly, the compounds according to the invention inhibit the release of ApoB-100-associated particles. The IC.sub.50 value indicates the concentration of substance at which the light adsorption is inhibited by 50% in comparison with the control (solvent control without substance).
TABLE______________________________________ Example No. IC.sub.50 �nM!______________________________________ 15 500 53 250 127 130 141 20______________________________________
2. Investigation of the inhibition of the proliferation of smooth muscle cells
The antiproliferative action of the compounds is determined using smooth muscle cells which are obtained from the aortas of rats by the media explant technique �R. Ross, J. Cell. Biol. 50, 172, 1971!. The cells are sown in suitable culture dishes, generally 96-well plates, and are cultured for 2-3 days in medium 199 with 7.5% of FCS and 7.5% of NCS, 2 mM L-glutamine and 15 mM HEPES, pH 7.4, in 5% of CO.sub.2 at 37.degree. C. Thereafter, the cells are synchronized by withdrawal of serum for 2-3 days and are then stimulated to growth with serum or other factors. At the same time, test compounds are added. After 16-20 hours, 1 .mu.Ci of .sup.3 H-thymidine is added, and after a further 4 hours the incorporation of this substance into the DNA of the cells which can be precipitated with TCA is determined. To determine the IC.sub.50 values, the active compound concentration which, on sequential diluent of the active compound, causes half the maximum inhibition of the thymidine incorporation caused by 10% of FCS.
3. Determination of VLDL secretion in vivo on the hamster
The effect of the test substances on VLDL secretion in vivo is investigated on the hamster. For this purpose, golden hamsters are premedicated with atropine (83 mg/kg s.c.) and anaesthetized with Ketavet (83 mg/kg s.c.) and Nembutal (50 mg/kg i.p.). When the animals have become free tom reflexes, the v. jugularis is exposed and a cannula is inserted. 0.25 ml/kg of a 20% strength solution of Triton WR-1339 in physiological saline solution is then administered. This detergent inhibits the lipoprotein lipase and thus leads to an increase in the triglyceride level because of an absence of catabolism of secreted VLDL particles. This increase in triglycerides can be used as a measure of the rate of VLDL secretion. Blood is taken from the animals by puncture of the retroorbital venous plexus before and one and two hours after administration of the detergent. The blood is incubated at room temperature for two hours and then at 4.degree. C. overnight in order to conclude the coagulation completely. Thereafter, it is centrifuged at 10,000 g for 5 minutes. The triglyceride concentration in the serum thus obtained is determined with the aid of a modified commercially obtainable enzyme test (Merckotest.RTM. Triglyceride No. 14354). 100 .mu.l of test reagent are added to 100 .mu.l of serum in 96-well plates and the mixtures are incubated at room temperature for 10 minutes. The optical density is then determined at a wavelength of 492 nm in an automatic plate reader (SLT-Spectra). Serum samples with too high a triglyceride concentration are diluted with physiological saline solution. The triglyceride concentration contained in the samples is determined with the aid of a standard curve measured in parallel. In this model test substances are administered either intravenously, immediately before administration of the detergent or orally or subcutaneously before initiation of the anaesthesia.
4. Inhibition of the intestinal absorption of triglycerides in vivo (rats)
The substances which are to be investigated for their triglyceride absorption-inhibiting action in vivo are administered orally to male Wistar rats having a body weight of between 170 and 230 g. For this purpose, the animals are divided into groups of 6 animals 18 hours before administration of the substance, and their food is then withdrawn. Drinking water is available to the animals ad libitum. The animals of the control group are given an aqueous tragacanth suspension or a tragacanth suspension which contains olive oil. The tragacanth-olive oil suspension is prepared with an Ultra-Turrax. The substances to be investigated are suspended in a corresponding tragacanth-olive oil suspension, likewise with the Ultra-Turrax, directly before administration of the substance.
Blood is taken from each rat by puncture of the retroorbital venous plexus before application of the stomach tube in order to determine basal serum triglyceride content. The tragacanth suspensions, tragacanth-olive oil suspensions without a substance (control animals) and the substances suspended in a corresponding tragacanth-olive oil suspension, are then administered to the fasting animals with a stomach tube. Further blood is taken for determination of the postprandial increase in serum triglycerides as a rule 1, 2 and 3 hours after application of the stomach tube.
The blood samples are centrifuged and, after isolation of the serum, the triglycerides are determined photometrically with an EPOS analyser 5060 (Eppendorf Geratebau, Netlacier & Hinz GmbH, Hamburg). The triglycerides are determined completely enzymatically with a commercially available UV test.
The postprandial increase in serum triglycerides is determined by subtraction of the triglyceride pre-value of each animal from its corresponding postprandial triglyceride concentrations (1, 2 and 3 hours after administration).
The differences (in mmol/l) at each point in time (1, 2 and 3 hours) are averaged in the groups, and the means of the increase in serum triglycerides (.DELTA.TG) of the animals treated with the substances are compared with those of the animals which were given only the tragacanth-oil suspension.
The course of the serum triglycerides of the control animals which were given only tragacanth is also calculated. The effect of the substance at each point in time (1, 2 or 3 hours) is determined as follows and stated in .DELTA.% of the oil-loaded control. ##EQU1##
Effect of 10 mg of test substance/kg of body weight p.o. on the increase in triglycerides (.DELTA.%) 2 h after a triglyceride loading in the serum of fasting rats. The increase in serum triglycerides of fat-loaded control animals based on the serum triglyceride level of tragacanth control animals corresponds to 100%. n=6 animals per group.
Statistical analysis is by the Student t-test after first checking the variances for homogeneity.
Substances which statistically significantly (p <0.05) reduce the postprandial increase in serum triglycerides by at least 30% at a point in time, compared with that of the untreated control group, are regarded as pharmacologically active.
5. Inhibition of VLDL secretion in vivo (rat)
The action of the test substances on VLDL secretion is also investigated in the rat. For this, 500 mg/kg of body weight (2.5 mg/kg) of Triton WR-1339, dissolved in physiological saline solution, are administered intravenously into the tail vein of rats. Triton WR-1339 inhibits the lipoprotein lipase and thus leads to an increase in the triglyceride and cholesterol level by inhibition of VLDL catabolism. These increases can be used as a measure of the rate of VLDL secretion.
Blood is taken from the animals by puncture of the retroorbital venus plexus before and one and two hours after administration of the detergent. The blood is incubated at room temperature for 1 h for coagulation and the serum is isolated by centrifugation at 10,000 g for 20 s. The triglycerides are then determined photometrically at a wavelength of 540 nm with a commercially available coupled enzyme test (Sigma Diagnostics.RTM., No. 339). The measurement is made at a wavelength of 546 nm with the aid of an enzyme test which is likewise coupled (Boehringer Mannhelm.RTM., No. 1442350). Samples with triglyceride or cholesterol concentrations which exceed the measurement range of the methods are diluted with physiological saline solution. The particular serum concentrations are determined with the aid of standard series measured in parallel. The test substances are administered orally, intravenously or subcutaneously immediately after the Triton injection.
The new active compounds can be converted in a known manner into the customary formulations, such as tablets, coated tablets, pills, granules, aerosols, syrups, emulsions, suspensions and solutions, using inert, non-toxic, pharmaceutically suitable excipients or solvents. The therapeutically active compound should in each case be present here in a concentration of about 0.5 to 90% by weight of the total mixture, i.e. in amounts which are sufficient to achieve the stated dosage range.
The formulations are prepared, for example, by extending the active compounds with solvents and/or excipients, if appropriate using emulsifying agents and/or dispersing agents, and in the case of the use of water as a diluent, for example, organic solvents can be used as auxiliary solvents if appropriate.
The administration is carried out in the customary manner, preferably orally or parenterally, in particular perlingually or intravenously.
In the case of parenteral use, solutions of the active compound can be employed, using suitable liquid carrier materials.
In general, it has proved advantageous in the case of intravenous administration to administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg of body weight, in order to achieve effective results, and in the case of oral administration the dosage is about 0.01 to 20 mg/kg preferably 0.1 to 10 mg/kg of body weight.
Nevertheless, it may be necessary to deviate from the amounts mentioned, and in particular as a function of the body weight or the nature of the administration route, of the behaviour of the individual towards the medicament, the nature of the formulation thereof and the time or interval at which administration takes place. Thus, in some cases it may be sufficient to manage with less than the abovementioned minimum amount, while in other cases the upper limit mentioned must be exceeded. In the event of administration of relatively large amounts, it may be advisable to distribute these into several individual doses over the day.
Definition of the isomer types:
4 dia=mixture of the four possible diastereomers with two centres of asymmetry in the molecule
dia A=diastereomer having the higher R.sub.f value
dia B=diastereomer having the lower R.sub.f value
ent=enantiomer p1 2 ent dia=mixture of two enantiomerically pure diastereomers
ent dia A=enantiomerically pure diastereomer having the higher R.sub.f value
ent dia B=enantiomerically pure diastereomer having the lower R.sub.f value
R=R enantiomer
rac=racemate
rac dia A=racemic diastereomer having the higher R.sub.f value
rac dia B=racemic diastereomer having the lower R.sub.f value
S=S enantiomer
Abbreviations used:
Ac=acetyl
Bn=benzyl
Bz=benzoyl
iBu=iso-butyl
nBu=normal butyl
sBu=secondary butyl
tBu=tertiary butyl
cDec=cyclo decyl
DMF=N,N,-dimethylformamide
DMSO=dimethyl sulphoxide
cDodec=cyclo-dodecyl
Et=ethyl
cHept=cyclo-heptyl
cHex=cyclo-hexyl
HOBT=1-hydroxy-1H-benzotriazole
Me=methyl
Mes=mesyl
cNon=cyclo-nonyl
cOct=cyclo-octyl
cPent=cyclo-pentyl
nPent=normal pentyl
Ph=phenyl
cPr=cyclo-propyl
nPr=normal propyl
iPr=iso-propyl
THF=tetrahydrofuran
TMS=tetramethylsilane
pTol=para-tolyl
pTos=para-tosyl
cUndec=cyclo-undecyl
______________________________________Solvent mixtures usedDesignation Mobile phase Ratio______________________________________A methylene chloride:ethyl acetate 1:1B methylene chloride:methanol 10:1C methylene chloride:methanol 20:1D methylene chloride:methanol 50:1E methylene chloride:methanol 25:1F methylene chloride:ethanol 20:1G methylene chloride:methanol 100:1H petroleum ether:ethyl acetate 2:1I toluene:ethyl acetate 4:1J petroleum ether:acetone 2:1K methylene chloride:ethyl acetate 5:1L petroleum ether:acetone 1:1M methylene chloride:ethyl acetate 4:1N toluene:ethyl acetate 1:1O petroleum ether:ethyl acetate 1:1P petroleum ether:acetone 3:1Q toluene:ethyl acetate 2:3R toluene:ethyl acetate 2:1S methylene chloride:ethyl acetate 10:1T petroleum ether:ethyl acetate 5:1U methylene chloride:methanol 5:1V petroleum ether:ethyl acetate 4:1W ethyl acetateX petroleum ether:ethyl acetate 3:2Y methylene chloride:ethanol 50:1Z methylene chloride:methanol 19:1AA toluene:ethanol 30:1AB toluene:ethanol 15:1AC methylene chloride:methanol:ethyl 90:10:1 acetateAD methylene 90:10:1 chloride:methanol:concentrated aqueous ammoniaAE petroleum ether:ethyl acetate 3:7AF petroleum ether:ethyl acetate 7:3AG petroleum ether:ethyl acetate 1:2AH petroleum ether:ethyl acetate 2:3AI petroleum ether:ethyl acetate 1:4AJ methylene chloride:methanol 9:1AK toluene:acetone 10:1AL toluene:acetone 40:1______________________________________
Preparation instruction for the TLC mobile phase BABA
87.9 ml of an aqueous 0.06667 molar potassium dihydrogen phosphate solution and 12.1 ml of an aqueous 0.06667 molar disodium hydrogen phosphate solution are mixed. 60 ml of the solution thus prepared are shaken with 200 ml of n-butyl acetate, 36 ml of n-butanol and 100 ml of glacial acetic acid and the aqueous phase is removed. The organic phase is the mobile phase BABA.
Starting compounds

EXAMPLE 1
Methyl 2-amino-2-�2'-(1',3'-dithiolano)!acetate hydrochloride ##STR27##
0.5 g (2.8 mmol) of 2-amino-2-�2'-(1',3'-dithiolano)!acetic acid (synthesis: M. P. Mertes. and A. A. Ramsey J. Med. Chem. 12, 342 (1969).) are reacted with 0.4 ml (5.6 mmol of thionyl chloride in 10 ml of methanol under reflux. After 8 hours, the mixture is cooled and evaporated to dryness in vacuo in a rotary evaporator, and residual solvent and excess reagents are then removed under a high vacuum over phosphorus pentoxide and solid sodium hydroxide.
Yield: 0.62 g
R.sub.f =0.32 (BABA) characteristic .sup.1 H-NMR signals (CD.sub.3 OD, 200 MHz, the solvent as the standard at 3.25 ppm): .delta.=4.36 (d, 1H); 5.17 (d, 1H) ppm.
The following compounds are obtained analogously to Example 1:
TABLE I__________________________________________________________________________ ##STR28##Example Literature/distributor of theNo. L/hydrochloride R.sub.f /solvent starting material__________________________________________________________________________II ##STR29## 0.39/BABA ##STR30## DE 21 62 717III ##STR31## 0.01/AHIV ##STR32## 0.01/AH ##STR33## 0.01/AH ##STR34## US 4 474 780VI ##STR35## 0.21/E ##STR36## DE 28 36 613VII ##STR37## 0.27/BABA ##STR38## R. M. Williams et al., J. Org. Chem. 55, 3723 (1990).VIII ##STR39## 0.46/BABA ##STR40## US 4 138 397IX ##STR41## 0.17/BABA ##STR42## DE 25 40 804X ##STR43## 0.20/BABA ##STR44## US 4 734 407XI ##STR45## 0.45/BABA ##STR46## US 4 734 407XII ##STR47## 0.58/BABA ##STR48## G. Schmidt et al. in "Recent Advances in Chemotherapy" Ed. D. Adam, H. Lode and E. Rubinstein, p.2428 et seq. Futuramed Publishers Munich, 1992.XIII ##STR49## 0.58/BABA ##STR50## US 4 734 407XIV ##STR51## 0.29/BABA ##STR52## US 4 748 163XV ##STR53## 0.40/BABA ##STR54## M. Hatanaka et al., J. Med. Chem. 16, 978 (1973).__________________________________________________________________________
Example XVI
3-Fluorophenylglycinol ##STR55##
18 ml of anhydrous THF are added to 71 ml of a 1M lithium alanate solution in THF and the mixture is heated under reflux. After the heating bath has been removed, 6.0 g of 3-fluorophenylglycine (E. L. Compete Jr. D. A. Weinstein, Synthesis 1977, 852) are added in small portions, the mixture is heated under reflux for a further hour and a solution of 1.27 g of potassium hydroxide in 5.1 ml of water is then carefully added dropwise. After a further 15 minutes under reflux, the precipitate formed is filtered off hot with suction and washed several times with THF. The filtrate is concentrated substantially (vacuum/rotary evaporator), the residue is taken up in ethyl acetate, the mixture is dried with sodium sulphate and evaporated again and the residue is stirred with petroleum ether, whereupon the product slowly solidifies. After filtration with severe suction and removal of the residual solvent in vacuo, 6.0 g of product are obtained.
R.sub.f =0.13 (B)
.sup.1 H-NMR (CD.sub.3 OD, 250 MHz, the solvent signal at 3.25 ppm serves as the standard): .delta.=3.48 (dd, 1H); 3.62 (dd, 1H); 3.89 (dd, 1H); 6.93 (m, 1H); 7.05-7.14 (m, 2H); 7.27 (m, 1H) ppm.
D,L-3-fluorophenylglycine is also commercially obtainable from K & K.
The following compounds are obtained analogously to Example XVI:
TABLE II______________________________________ ##STR56##Example Distributor of theNo. L R.sub.f /solvent starting material______________________________________XVII ##STR57## 0.18/B AldrichXVIII ##STR58## 0.09/B FlukaXIX ##STR59## 0.23/B K & KXX ##STR60## 0.12/B K & K______________________________________
Example XXI
E- and Z-(isoquinolin-1-yl)phenyl ketoxime ##STR61##
15.0 g of 1-benzoylisoquinoline (J. Knabe and A. Frie, Arch. Pharm. 306, 648 (1973).) and 8.94 g of hydroxyammonium chloride are boiled under reflux in 50 ml of pyridine for 4 hours. The cooling reaction mixture is stirred into 500 ml of water at room temperature. After the mixture has been subsequently stirred vigorously for 15 minutes, the precipitate is filtered off with suction, washed several times with water, finally filtered off under a very severe suction and then dried under a high vacuum over phosphorus pentoxide at about 80.degree. C.
Yield: 15.9 g
R.sub.f =0.44 (C)
MS (Chemical ionization with NH.sub.3): m/z=249 (�M+H!.sup.+, 17%), 248 (M.sup.+, 18%).
The following compounds are prepared analogously to the preparation instructions of Example XXI:
TABLE III______________________________________ ##STR62## Literature for theEx. No. X R' R" R.sub.f (solvent) starting material______________________________________XXII S CH.sub.3 CH.sub.3 0.73/0.53 (C) Y. Oka et al., Chem. Pharm. Bull. 18, 527 (1970)XXIII NH H H 0.30/0.26 (B) A. Sonn et al., Chem. Ber. 66, 1900 (1933)______________________________________
Example XXIV
1-(.alpha.-Aminobenzyl)-isoquinoline ##STR63##
15.72 g of the compound from Example XXI and 6.05 g of ammonium acetate are suspended in 236 ml of concentrated aqueous ammonia solution, 157 ml of water and 157 ml of ethanol, and a total of 22.7 g of zinc dust are then added in portions under reflux over a period of one hour. After 3 hours under reflux, the mixture is cooled to room temperature, a pH of 14 is established with 10% strength aqueous sodium hydroxide solution (10 g of solid NaOH per 90 ml of water) and the mixture is extracted several times with ether. The organic phases are dried with sodium sulphate, evaporated and freed from the residual solvent under a high vacuum.
Yield: 12.4 g
R.sub.f =0.13 (B) characteristic .sup.1 H-NMR signal (CDCl.sub.3, 250 MHz, TMS): .delta.=5.95 (s, 1H, CH--NH.sub.2) ppm.
The following compounds can be prepared analogously to the preparation of Example XXIV:
TABLE IV______________________________________ ##STR64## Ex. No. of theEx. No. X R' R" R.sub.f (solvent) starting material______________________________________XXV S CH.sub.3 CH.sub.3 0.38 (C) XXIIXXVI NH H H 0.13 (B) XXIII______________________________________
TABLE V______________________________________ ##STR65##Example Literature/distributor ofNo. L R.sub.f /solvent the starting material______________________________________XXVII ##STR66## 0.10 (B) ##STR67## F. Rose-Munch et al., J. Organomet. Chem. 415, 223 (1991)XXVIII ##STR68## 0.01 (O) ##STR69## G. H. Hakimelahi and G. Just, Can. J. Chem. 57, 1932 (1979)XXIX ##STR70## 0.19 (U) Precursor = Ex. No. IV______________________________________
Example XXX
(R,S)-2-Benzyl-4-hydroxy-butyric acid amide ##STR71##
12.0 g of (R,S)-2-Benzyl-4-hydroxy-.gamma.-butyrolactone (Z. Jedlinski et al., J. Org. Chem. 52, 4601 (1987).) are reacted in a saturated solution of ammonia in methanol at room temperature. After 20 hours, the solvent is evaporated off in vacuo with the excess reagent, the residue is taken up again in methanol and the mixture is evaporated in order to remove the excess ammonia completely. The resulting solid is subsequently dried in a desiccator over phosphorus pentoxide.
Yield: 13.5 g
R.sub.f =0.39 (B)
MS (EI): m/z=193 (5%, M.sup.+), 176 (25%, M.sup.+ --NH.sub.3); 162 (9% , M.sup.+ --CH.sub.2 OH); 148 (56%, M.sup.+ --NH.sub.3 --CO); 91 (100%, C.sub.6 H.sub.5 CH.sub.2.sup.+).
Example XXXI
4-Amino-(R,S)-3-benzyl-butan-1-ol ##STR72##
11.6 g of the compound from Example XXX are reacted with 4.55 g of lithium alanate in 100 ml of THF (anhydrous) at room temperature. After 20 hours, the reaction is interrupted by addition of 45 ml of saturated aqueous sodium chloride solution, and the mixture is subsequently stirred vigorously for one hour and filtered off with suction over kieselguhr. The eluate is taken up in toluene (addition of ethanol may be necessary for complete dissolation) and the water is carried off with the organic solvent by evaporation, taking up in toluene again and renewed evaporation.
Yield: 11.3 g
R.sub.f =0.23 (methylene chloride: methanol: glacial acetic acid=5:1:1)
The crude product is reacted further without purification.
The synthesis of the precursor carboxylic acids are known, in this context of, for example, U.S. Pat. No. 4,929,629, U.S. Pat. No. 4,970,215, EP 509 359, U.S. 4,929,626, U.S. Pat. No. 5,091,392, U.S. Pat. No. 5,126,354, EP 414 078, EP 529 450).
Example XXXII and Example XXXIII
2-(R)- and 2-(S)-2-{4-�(Quinolin-2-yl)methoxy!phenyl}-2-cyclopentyl-acetic acid (R)-phenylglycinolamide ##STR73##
2.5 g (6.9 mmol) of racemic 2-{4-�(quinolin-2-yl)methoxy!phenyl}-2-cyclopentyl acetic acid (synthesis: U.S. Pat. No. 4,970,215) are dissolved in 25 ml of anhydrous N,N-dimethylformamide, 2.88 ml (20.8 mmol) of triethylamine and 604.7 .mu.l (7.6 mmol) of mesyl chloride are added and the mixture is subsequently stirred at -60.degree. C. for 3 hour under argon as an meat gas. Thereafter, 1.14 g (8.3 mmol) of (R)-phenylglycinol (commercially obtainable from Aldrich) and 0.84 g (6.9 mmol) of 4-(N,N-dimethylamino)-pyridine, dissolved in 20 ml of anhydrous N,N-dimethylformamide, are added and the mixture is subsequently stirred for a total of 16 hours while slowly warning to room temperature. Ethyl acetate and water are added to the reaction mixture and the aqueous phase is brought to a pH of about 2 with 1M hydrochloric acid. The organic phase is extracted several times with dilute hydrochloric acid (pH-2), washed with water and then extracted several times with 0.1M aqueous sodium hydroxide solution. The organic phase is again washed with water and then dried with anhydrous magnesium sulphate and evaporated. Column chromatography (silica gel 60, Merck 40-63 .mu.m, mobile phase, petroleum ether, ethyl acetate from 5:1 to 1:1) is carried out to separate the components.
Example XXXII:
R.sub.f =0.12 (K)
Yield: 1.1 g
Example XXXIII:
R.sub.f =0.08 (K)
Yield: 1.0 g
The absolute configuration of the enantiomercially pure carboxylic acids (starting material for Examples XXXII and XXXIII) is known (EP 509 359), so that the absolute configuration of the products (Example XXXII and XXXIII) can be deduced therefrom. The .sup.1 H-NMR spectra of the two diastereomeric products (200 MHz, d.sub.6 -DMSO, TMS for Example XXXII/250 MHz, d.sub.6 -DMSO, TMS for Example XXXIII) shows significant differences in the aromatic range:
the H signals of the phenyl radical of the phenylglycinolamide from Example XXXII are thus at about 7.1 ppm, and in the ease of Example XXXIII they are at about 7.3 ppm. This finding can be applied to many derivatives of this type.
Example XXXIV
2-(S)-2-{4-�(Quinolin-2-yl)methoxy!phenyl}-2-cycloheptyloacetic acid (R)-phenylglycinolamide ##STR74##
The title compound is prepared analogously to the instructions of Examples XXXII and XXXIII.
Melting point=176.degree. C.
Example XXXV
(2-Hydroxy-phenyl)-glycinol hydrochloride ##STR75##
2.18 g (10 mmol) of (2-hydroxy-phenyl)-glycine methyl ester hydrochloride are dissolved in 20 ml of dry THF and reacted with 3.34 g (33 mmol) of triethylamine and 2.39 g (22 mmol) of trimethylchlorosilane at room temperature (25.degree. C.) for 18 hours. The precipitate formed is filtered off with suction, and washed with dry THF and the filtrate is reacted with lithium alanate (0.76 g/38.0 mmol) at 25.degree. C. Thereafter, excess reagent is filtered off with suction, the residue is rinsed with dry THF, water is added and the mixture is diluted with ether (pH.about.10). The aqueous phase is brought to pH=2 with 2M hydrochloric acid, washed with ether and lyophilized
Yield 1.20 g (6.3 mmol)
R.sub.f =0.38 (BABA)
The compounds listed in Table VI are prepared analogously to the instructions of Example XXXV.
TABLE VI______________________________________ ##STR76##Example No. R.sup.34 R.sub.f (mobile phase)______________________________________XXXVI 3-OH 0.23 (U)XXXVII 4-OH 0.34 (BABA)______________________________________
The compounds of Table VII are prepared analogously to the instructions of Example No. 1:
TABLE VII______________________________________ ##STR77##Example No. L m.p. �.degree.C.! R.sub.f (solvent)______________________________________XXXVIII ##STR78## 0.01 (AH)XXXIX ##STR79## 0.00 (AH)XL ##STR80## 0.01 (AH)XLI ##STR81## 0.01 (AH)XLII ##STR82## 0.01 (AH)XLIII ##STR83## 0.01 (AH)XLIV ##STR84## 0.01 (AH)______________________________________
PREPARATION EXAMPLES
Example 1
(2S)-2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cyclopentyl-acetic acid (R)-(O-acetyl)-phenylglycinolamide ##STR85##
30 mg of the compound from Example XXXII are reacted with 13.4 .mu.l of acetyl chloride and 15.1 .mu.l of pyridine in 20 ml of methylene chloride at room temperature. After 20 hours, the mixture is poured onto 1M hydrochloric acid and the organic phase is then washed with a buffer solution of pH 2 (ready-to-use buffer solution, pH=2.00, citrate-hydrochloric acid based on SMR of NIST, Merck order No. 9433.1000). The organic phase is dried with magnesium sulphate and evaporated and the residue is freed from the residual solvent under a high vacuum.
Yield: 29 mg.
R.sub.f =0.47 (F)
Example 2
(2S)-2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid (S)-(O-acetyl)-phenyl-glycinol-amide ##STR86##
(2S)-2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid (S)-phenylglycinolamide U.S. Pat. No. 4,970,215) is reacted analogously to the instructions of Example 1 to give the title compound.
Melting point: 143.degree. C.
The compounds from Tables 1 and 2 can be prepared analogously to Example XXXII and XXXIII:
TABLE 1__________________________________________________________________________ ##STR87## Example No./literature forExample No. 1 2 R.sup.35 R.sub.f /solvent the precursor amine__________________________________________________________________________3 rac rac 2-OH 0.25/D Example II4 rac rac 3-OH 0.19/D DE 22 04 1175 rac rac 4-OH 0.18/D EP 530 8796 rac rac 2-OMe 0.31/D S. J. Daum et al., Syn. Commun. 11, 1 (1981).7 rac rac 3-OMe 0.15/G DE 23 09 1808 rac rac 4-OMe 0.35/D H. E. Baumgarten et al., J. Org. Chem. 31, 3708 (1966).9 rac rac 4-tBu 0.36/H WO 91/08 70410 rac rac 4-cPr 0.41/I Example III11 rac rac 4-Ph 0.53/J Example IV12 rac rac ##STR88## 0.44/I Example V13 rac rac ##STR89## 0.63/E Example VI__________________________________________________________________________
TABLE 2______________________________________ ##STR90## Example No.Example No. 1 2 R.sup.35 R.sub.f /solvent of the precursor______________________________________14 rac rac 2-F 0.61/A Example XVII15 rac rac 3-F 0.57/A Example XVI16 rac rac 4-F 0.50/A Example XVIII17 rac rac 3-Cl 0.61/B Example XIX18 rac rac 4-Cl 0.72/B Example XX19 rac rac 3,4-OCH.sub.2 O 0.48/A Example XXVIII20 rac rac 4-Me 0.60/A Example XXVII______________________________________
Example 21
2-{4-�Quinolin-2-yl-methoxy!phenyl}-2-cyclopentyl acetic acid �4-tert-butylphenyl!glycinol-amide ##STR91##
0.78 mg of the compound from Example 9 is reacted in 10 ml of anhydrous THF with 3.05 ml of a 1M solution of lithium alanate in THF at room temperature. After 100 minutes, the mixture is poured onto ethyl acetate/water, the organic phase is washed with saturated aqueous sodium chloride solution and the organic phase is dried with magnesium sulphate and evaporated to dryness. The resulting crude product is purified by column chromatography (silica gel 60, Merck 40-63 .mu.m, first methylene chloride and then a mixture of methylene chloride:methanol of first 200:1 and then 100:1, 50:1 to 20:1 is used as the mobile phase).
Yield: 0.38 g
R.sub.f =0.46 (E)
The compounds from Table 3 are prepared analogously to the instructions of Example 21:
TABLE 3______________________________________ ##STR92##Exam- Example No. of theple No. 1 2 R.sup.36 R.sub.f /solvent precursors______________________________________22 rac rac 4-cPr 0.33/E Example 1023 rac rac 4-Ph 0.27/A Example 1124 rac rac ##STR93## 0.42/E Example 1225 rac rac ##STR94## 0.63/B Example 1326 rac dia A 4-Ph 0.36/F Example 1127 rac dia B 4-Ph 0.36/F Example 1128 rac rac 2-OH 0.40/C Example 329 rac rac 3-OH 0.40/B Example 430 rac rac 4-OH 0.34/B Example 531 rac rac 2-OMe 0.09/D Example 632 rac dia A 3-OMe 0.29/C Example 733 rac rac 3-OMe 0.29/C Example 734 rac rac 4-OMe 0.36/C Example 8______________________________________
TABLE 4______________________________________ ##STR95## Example No./Exam- literature for theple No. 1 2 Het R.sub.f /solvent precursor amine______________________________________35 rac rac ##STR96## 0.97/K Example VII36 rac rac ##STR97## 0.40/O Example VIII37 rac rac ##STR98## 0.30/K Example IX38 rac rac ##STR99## 0.24/P Example X39 rac rac ##STR100## 0.67/C Example XI40 rac rac ##STR101## 0.43/B Example XII41 rac rac ##STR102## 0.38/C Example XIII42 rac rac ##STR103## 0.30/Q Example XIV43 rac rac ##STR104## 0.65/K DE 22 04 11744 rac rac ##STR105## 0.60/K Example XV45 rac rac ##STR106## 0.50/R Example I______________________________________
TABLE 5__________________________________________________________________________ ##STR107## Example No. Preparation analogouslyExample No. 1 2 Het R.sub.f /solvent precursor to Example No.__________________________________________________________________________46 rac rac ##STR108## 0.2/K Example 35 2147 rac rac ##STR109## 0.48/A Example XXVIII XXXII, XXXIII48 rac rac ##STR110## 0.22/E Example 36 2149 rac rac ##STR111## 0.33/B Example 37 2150 rac rac ##STR112## 0.2/L Example 38 2151 rac rac ##STR113## 0.2/C Example 39 2152 rac rac ##STR114## 0.39/B Example 42 2153 rac rac ##STR115## 0.14/K Example 43 2154 rac rac ##STR116## 0.1/M Example 44 2155 rac rac ##STR117## 0.36/N Example 45 21__________________________________________________________________________
TABLE 6__________________________________________________________________________ ##STR118## Distributor/literature/ Analogously to Example No. of the instructions in ExampleExample No. 1 E R.sub.f /solvent starting material No.__________________________________________________________________________56 S ##STR119## 0.35/H DE 22 04 117 Example XXXII/ XXXIII57 S ##STR120## 0.33/S Example XV Example XXXII/ XXXIII58 S ##STR121## 0.2/0.14/M Example 56 Example 2159 S ##STR122## 0.21/0.14/M Example 57 Example 2160 S ##STR123## 0.3/0.25/D Example XXIX Example XXXII/ XXXIII61 S ##STR124## 0.30/D Example XXIX Example XXXII/ XXXIII62 S ##STR125## 0.25/D Example XXIX Example XXXII/ XXXIII__________________________________________________________________________
TABLE 7__________________________________________________________________________ ##STR126## Example No./Literature forExample No. 1 2 Het R.sub.f /solvent the precursor amine__________________________________________________________________________63 rac rac ##STR127## 0.31/J E. Niemers et al., Synthesis 1976, 593.64 rac rac ##STR128## 0.18/J E. Niemers et al., Synthesis 1976, 593.65 rac rac ##STR129## 0.18/J E. Niemers et al., Synthesis 1976, 593.66 rac rac ##STR130## 0.37/J Example XXIV67 rac rac ##STR131## 0.59/M T.P. Sycheva et al., Chem. Heterocycl. Compounds 1966, 529.68 rac rac ##STR132## 0.65/B Example XXV69 rac rac ##STR133## 0.61/M US 44 25 33870 rac rac ##STR134## 0.61/B V. M. . Aruyzina et al., Chem. Heterocycl. Compounds 1966, 460.71 rac rac ##STR135## 0.17/K Samia M. Rida et al., Pharmazie 41, 563 (1986).72 rac rac ##STR136## 0.25/A Example XXVI__________________________________________________________________________
Example 73
2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid (phenylglycine ethyl ester)-amide ##STR137## (R,S)-2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid (U.S. Pat. No. 4,970,215) and D,L-phenylglycine ethyl ester (Maybridge) are reacted with one another analogously to the preparation instructions of Examples XXXII and XXXlII
R.sub.f =0.12 (T)
Example 74
2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid (phenylglycine)-amide ##STR138##
18.2 g of the compound from Example 73 are reacted with 160 ml of aqueous 2M sodium hydroxide solution in 40 ml of ethanol under reflux. After 2.5 hours, most of the ethanol content is removed in vacuo. The partly concentrated reaction mixture is diluted with water and extracted several times with ether. Thereafter, the residual content of organic solvent is stripped off from the aqueous phase in vacuo, a pH of 2 is established with 2M hydrochloric acid at 0.degree. C. and the precipitate which is obtained is filtered off with suction, The precipitate is washed several times with water and, after the last filtration suction, is dried in vacuo over phosphorus pentoxide and solid sodium hydroxide.
Yield: 11.8 g
R.sub.f =0.21 (B)
Example 75
2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cycloheptyl acetic acid N-(phenylglycinamide)amide ##STR139##
200 mg of the compound from Example 73 is dissolved in a saturated solution of ammonia in methanol and reacted under reflux for one day. The reaction mixture is evaporated in vacuo and finally dried over phosphorus pentoxide under a high vacuum.
Yield: 190 mg
R.sub.f =0.28 (C)
TABLE 8__________________________________________________________________________ ##STR140## Literature/Ex. No. of the starting Preparation analogouslyEx. No. 1 2 R.sup.37 R.sub.f /solvent material to Ex. No.__________________________________________________________________________76 rac rac CONHCH.sub.3 0.39/C Example 73 75**77 rac rac CON(CH.sub.3).sub.2 0.33/D Example 74 XXXII/XXXIII78 rac rac CONHnBu 0.15/D Example 73 75**79 rac rac ##STR141## 0.55/B Example 73 75**80 rac rac ##STR142## 0.3/U Example 73 75***81 rac rac ##STR143## 0.53/C Example 74 XXXII/XXXIII82 rac rac ##STR144## 0.2/B Example 81 7483 rac rac ##STR145## 0.38/C Example 74 XXXII/XXXIII84 rac rac ##STR146## 0.28/D Example 74 XXXII/XXXIII85 rac rac ##STR147## 0.18/D Example 74 XXXII/XXXIII86 rac rac ##STR148## 0.41/D Example 74 XXXII/XXXIII87 rac rac ##STR149## 0.34/D Example 74* XXXII/XXXIII__________________________________________________________________________ *the precursor amine (tertbutyl 1piperazinecarboxylate) is commercially obtainable from Aldrich. **the reaction solvent is ethanol ***the amine to be reacted is the reaction solvent.
2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid N-�.alpha.-(piperazin-1-yl-carbonyl)benzyl!amide ##STR150##
0.63 g of the compound from Example 87 is dissolved in 5 ml of ethyl acetate and reacted with 8 ml of 4M hydrochloric acid at room temperature. After 23 hours, ethyl acetate is added and the organic phase is extracted with 2M hydrochloric acid. The acid aqueous phase is freed from the organic residual solvent in vacuo and brought to pH 14 with 10% strength sodium hydroxide solution (10 g of solid NaOH in 90 ml of water) at about 10.degree. C. The precipitate obtained is filtered off with suction, washed with water and dried in vacuo over phosphorus pentoxide.
Yield: 0.48 g
R.sub.f =0.19 (C)
Example 89
2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid N-�.alpha.-(4-N-acetylpiperazin-1-yl-carbonyl)benzyl!amide ##STR151##
150 mg of the compound from Example 88 are reacted with 0.04 ml of triethylamine and 0.018 ml of acetyl chloride in 4 ml of methylene chloride at room temperature. After 1.5 hours, the mixture is extracted with a buffer of pH 4, the aqueous phase is shaken with methylene chloride and, after drying with sodium sulphate, the organic phase is evaporated. The crude product is purified by column filtration (silica gel 60, Merck 63-200 .mu.m, methylene chloride).
Yield: 160 mg
R.sub.f =0.36 (methylene chloride: methanol=20:1)
Example 90
2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cycloheptyl-acetic acid N-�.alpha.-(4N-methanesulphonyl-piperazin-1-yl-carbonyl)benzyl!amide ##STR152##
The compound from Example 88 is reacted with methanesulphonyl chloride analogously to the preparation of Example 89.
TABLE 9__________________________________________________________________________ ##STR153## Distributor/literatureEx. R.sub.f /solvent/ of the precursor Preparation analogouslyNo. 1 2 R.sup.38 melting point amines to Ex. No.__________________________________________________________________________91 S R CO.sub.2 CH.sub.3 0.43/X Nipkayaku XXXII/XXXIII92 S R COOH m.p. = 194-196.degree. C. Example 91 Example 7493 rac rac CO.sub.2 C.sub.2 H.sub.5 0.5/D Maybridge XXXII/XXXIII94 S R CH.sub.3 m.p. = 146.degree. Aldrich XXXII/XXXIII95 rac rac C.sub.2 H.sub.5 0.29/D Norse XXXII/XXXIII96 S rac CONH.sub.2 0.26/Z Example 91 Example 7597 rac rac CONHCH.sub.3 0.49/C Example 93 Example 75*98 rac rac ##STR154## 0.56/B Example 93 Example 75*99 rac rac CN 0.34/D Aldrich XXXII/XXXIII100 rac rac CF.sub.3 0.22/T J. R. McCarthy et al., XXXII/XXXIII Tetrahedron Lett. 31, 5547 (1990).101 rac rac ##STR155## 0.49/B Example 93 Example 75*__________________________________________________________________________ *The reaction solvent is ethanol.
Example 102
(2S)-2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cycloheptyl-acetic acid N-(1-phenylvinyl)amide ##STR156##
2.0 g of the compound from Example XXXIV are reacted with 0.545 ml of triethylamine and 0.304 ml of mesyl chloride in 20 ml of anhydrous DMF at -30.degree. C. After 2 hours, a further 1.09 ml of triethylamine are added and the mixture is warmed to room temperature. After the mixture has been subsequently stirred for 20 hours, it is brought to pH 2 with 2M hydrochloric acid and extracted with an ether/ethyl acetate mixture. The organic phases are dried with magnesium sulphate and evaporated. The crude material obtained is purified by column chromatography (silica gel 60, Merck 40-63 .mu.m, petroleum ether:ethyl acetate first 5:1 then 2:1).
Yield: 1.3 g
R.sub.f =0.20 (T) characteristic .sup.1 H-NMR signals (CDCl.sub.3, 200 MHz, TMS): .delta.=4.55 (dd, 1H); 5.16 (dd, 1H) (vinyl protons) ppm.
The compounds of the following Table 10 are prepared analogously to the instructions for Example 102:
TABLE 10______________________________________ ##STR157##Example No. 1 R.sup.2 R.sub.f /solvent______________________________________103 S ##STR158## 0.84/O104 rac ##STR159## 0.90/B105 rac CH.sub.3 0.70/A106 rac ##STR160## 0.97/B107 rac ##STR161## 0.98/B______________________________________
TABLE 11__________________________________________________________________________ ##STR162## Example No./ R.sub.f /solvent/ Distributor of the Preparation analogouslyEx. No. 1 2 R.sup.39 melting point precursor amines to Ex. No.__________________________________________________________________________108 S / H m.p. = 143.degree. C. Aldrich XXXII/XXXIII109 S R Et m.p. = 167-170.degree. C. Aldrich XXXII/XXXIII (toluene)110 S R iBu m.p. = 155.degree. C. Aldrich XXXII/XXXIII (toluene)111 S / CH.sub.2 OH 0.20 (W) Aldrich XXXII/XXXIII112 S S CO.sub.2 Me m.p. = 173-175.degree. C. Aldrich XXXII/XXXIII113 S S COOH m.p. = 183-185.degree. C. Example 112 Example 74__________________________________________________________________________
TABLE 12__________________________________________________________________________ ##STR163## Example No./literature/ distributor of the precursorEx. No. 1 R.sup.40 R.sub.f /solvent amines__________________________________________________________________________114 rac ##STR164## 0.26/C Aldrich115 S ##STR165## m.p. = 158.degree. C. (ethanol) Aldrich116 R ##STR166## m.p. = 132.degree. C. (toluene/ ethyl Aldrich)117 rac ##STR167## 0.73/B DE 26 28 469118 rac ##STR168## 0.77/B DE 26 28 469119 rac ##STR169## 0.51/C DE 26 28 469120 rac ##STR170## 0.21/D H.V. Sccor et al., J. Org. Chem. 43, 2539 (1978).121 rac ##STR171## 0.13/D Khim. Farm. Zh. 25, 60 (1991)122 rac ##STR172## 0.94/B Example XXXI123 rac ##STR173## 0.76/B Sigma124 rac ##STR174## 0.15/D WO 91/18 897125 rac ##STR175## 0.19/C DE 36 43 012__________________________________________________________________________
TABLE 13______________________________________ ##STR176## Literature/distributorEx. of the precursorNo. 1 E R.sub.f /solvent amines______________________________________126 S ##STR177## 0.51/D Aldrich127 S ##STR178## 0.80/V Aldrich128 S ##STR179## 0.13/D P & B129 S ##STR180## 0.51/O EP 514 267______________________________________
TABLE 14__________________________________________________________________________ ##STR181##Ex. No. 1 2 X' Y' R.sub.f /solvent Literature of the starting compounds__________________________________________________________________________130 rac rac CON(CH.sub.3) CH.sub.2 OH 0.89/B GB 14 34 826.131 rac rac CONH CH.sub.2 OCH.sub.3 0.17/G A. I. Meyers et al., J. Org. Chem. 43, 892 (1978).132 rac rac CON(CH.sub.3) CH.sub.2 OCH.sub.3 0.19/G B. E. Rossiter et al., Tetrahedron 49, 965 (1993).133 rac rac COO CH(OC.sub.2 H.sub.5).sub.2 0.68/D P. Tinapp, Arch. Pharm. 310, 89 (1977).134 rac dia A COS CH.sub.2 OH 0.42/H Y. Gareau et al., Tetrahedron Lett. 34, 3363 (1993).135 rac dia B COS CH.sub.2 OH 0.39/H Y. Gareau et al., Tetrahedron Lett. 34, 3363 (1993).__________________________________________________________________________
Example 136
(.alpha.-Formyl)benzyl 2-�4-(quinolin-2-yl-methoxy)-phenyl!-2-cyclopentyl-acetate ##STR182##
3.5 g of the compound from Example 133 are dissolved in 60 ml of dioxane and reacted with 20 ml of concentrated hydrochloric acid at room temperature for 4 hours. The mixture is then extracted with a mixture of ether and aqueous sodium carbonate solution. The organic phase is washed with water, dried with magnesium sulphate and evaporated. The crude product is purified by column chromatography (silica gel 60, Merck, 40-63 .mu.m, petroleum ether:ethyl acetate=first 4:1, then 2:1, finally 1:1).
Yield: 1.7 g
R.sub.f =0.10 (V)
Example 137
(.alpha.-Hydroxymethyl)benzyl 2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetate ##STR183##
0.46 g of the compound from Example 136 is reacted with 40 mg of sodium boronate in 20 ml of ethanol at room temperature. After 30 minutes, the mixture is poured onto water and extracted with ethyl acetate. The organic phases are dried with magnesium sulphate and freed from the solvent in vacuo. The resulting crude product is purified by column chromatography (silica gel 60, Merck, 40-63 .mu.m, petroleum ether:ethyl acetate=7:1, later 3:1).
Yield: 0.12 g
R.sub.f =0.41 (H)
Example 138
(.alpha.-Acetoxymethyl)-thiobenzyl 2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetate ##STR184##
The compound (diastereomer mixture) from Example 134 and 135 can be converted into the title compound analogously to the instructions for Example 89.
R.sub.f =0.28 (T)
TABLE 15__________________________________________________________________________ ##STR185##Example absolute con- R.sub.f (solvent)/ Distributor ofNo. figuration (1) R.sup.2 R.sup.41 melting point the benzylamines__________________________________________________________________________139 S ##STR186## H m.p. = 138.degree. C. Aldrich140 R ##STR187## H m.p. = 134.degree. C. Aldrich141 S ##STR188## H 0.41 (D) Aldrich142 R ##STR189## H 0.41 (D) Aldrich143 S ##STR190## 2-Cl 0.31 (Y) Aldrich144 S ##STR191## 3-Cl 0.26 (Y) Maybridge145 S ##STR192## 4-Cl 0.30 (Y) Aldrich146 S ##STR193## 4-F 0.32 (Y) Aldrich__________________________________________________________________________
Example 147
(2R)-�4-(quinolin-2-yl-methoxy)-phenyl!-2-cyclopentyl-acetic acid (S)-(O-acetyl)phenyl-glycinol-amide ##STR194##
(2R)-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid (S)-phenylglycinolamide �U.S. Pat. No. 4,970,215! is reacted analogously to the instructions of Example 1 to give the title compound.
R.sub.f =0.47 (ethanol:methylene chloride=1:20)
m.p.=173.degree. C.
TABLE 16__________________________________________________________________________ ##STR195## Starting material (amine) a) LiteratureExample No. 1 2 R.sup.42 Melting point �.degree.C.! b) Distributing company__________________________________________________________________________148 R S Me m.p. = 157.degree. C. b) Aldrich149 R S CH.sub.2 OMe m.p. = 147.degree. C. a) A. I. Meyers et al., J. Org. Chem. 43, 892 (1978).150 S S CH.sub.2 OMe m.p. = 146.degree. C. a) A. I. Meyers et al., J. Org. Chem. 43, 892 (1978).151 R R Me m.p. = 145.degree. C. b) Aldrich152 S R Me m.p. = 163.degree. C. b) Aldrich__________________________________________________________________________
TABLE 17__________________________________________________________________________ ##STR196##Example No. 1 ##STR197## R.sub.f value (solvent) Melting point Starting material a) Literature b) Distributing company* c) Preparation analogously to Ex. No.__________________________________________________________________________153 R Et m.p. = 142.degree. C. b) Aldrich154 S Et m.p. = 145.degree. C. b) Aldrich155 R CH.sub.2 CH.sub.2 OH m.p. = 143.degree. C. a) Aldrich156 rac CH.sub.2 CH.sub.2 OH m.p. = 130.degree. C. b) Aldrich157 rac CH.sub.2 COOH m.p. = 182-185.degree. C. c) analogously to Ex. No. 74 (from Ex. No. 158)158 rac CH.sub.2 CO.sub.2 Me m.p. = 134-136.degree. C. b) Aldrich159 S ##STR198## m.p. = 176.degree. C.160 R ##STR199## m.p. = 123.degree. C.161 S ##STR200## m.p. = 134.degree. C. b) Aldrich162 R ##STR201## m.p. = 184.degree. C. b) Aldrich163 R ##STR202## m.p. = 168.degree. C. b) Aldrich164 R ##STR203## m.p. = 170.degree. C. b) Aldrich165 S ##STR204## m.p. = 142.degree. C. b) Aldrich166 R ##STR205## m.p. = 158.degree. C. b) Sigma167 S ##STR206## m.p. = 186.degree. C. b) Sigma168 S ##STR207## m.p. = 160.degree. C. b) D-Schuchardt169 R ##STR208## m.p. = 137.degree. C. b) D-Schuchardt170 S ##STR209## m.p. = 139.degree. C. b) D-Schuchardt171 R ##STR210## m.p. = 160.degree. C. b) D-Schuchardt172 S ##STR211## R.sub.f = 0.48 (AA) b) Sigma173 R ##STR212## R.sub.f = 0.43 (AA) b) Sigma174 R ##STR213## m.p. = 233.degree. C. b) Sigma175 S ##STR214## m.p. = 234.degree. C. b) Sigma176 R ##STR215## m.p. = 219.degree. C. b) Sigma177 S ##STR216## m.p. = 214.degree. C. b) Sigma178 R ##STR217## R.sub.f = 0.12 (W) m.p. = 161.degree. C. b) Aldrich179 S ##STR218## m.p. = 152.degree. C. n) Aldrich180 R ##STR219## m.p. = 154.degree. C. b) Aldrich181 R ##STR220## m.p. = 155.degree. C. b) Aldrich182 S ##STR221## m.p. = 164.degree. C. b) Aldrich183 R ##STR222## m.p. = 134.degree. C. b) Aldrich184 R ##STR223## m.p. = 200.degree. C. b) Sigma185 S ##STR224## m.p. = 190.degree. C. b) Sigma186 R ##STR225## m.p. = 168.degree. C. b) Aldrich187 R ##STR226## R.sub.f = 0.37 (AF) a) G. Bittner et al., Justus Liebigs Ann. Chem. 713, 1 (1968)188 R ##STR227## R.sub.f = 0.18 (X) b) P & B189 S ##STR228## R.sub.f = 0.45 (X) b) P & B190 R ##STR229## R.sub.f = 0.01 (AH) c) analogously to Ex. No. 74 (from Ex. No. 193)191 S ##STR230## R.sub.f = 0.02 (AH) c) analogously to Ex. No. 74 (from Ex. No. 192)192 S ##STR231## R.sub.f = 0.14 (AH) b) Chemalog193 R ##STR232## R.sub.f = 0.21 (AH) b) Chemalog194 R ##STR233## R.sub.f = 0.01 (AE) c) analogously to Ex. No. 74 (from Ex. No. 195)195 R ##STR234## R.sub.f = 0.21 (AH) b) Chemalog196 R ##STR235## R.sub.f = 0.38 (D) b) Fluka197 S ##STR236## R.sub.f = 0.50 (X) b) Sigma198 S ##STR237## R.sub.f = 0.02 (X) c) analogously to Ex. No. 74199 R ##STR238## R.sub.f = 0.02 (X) c) analogously to Ex. No. 74200 S ##STR239## R.sub.f = 0.01 (X) c) analogously to Ex. No. 74201 R ##STR240## R.sub.f = 0.01 (X) c) analogously to Ex. No. 74202 R ##STR241## R.sub.f = 0.50 (X) b) Sigma__________________________________________________________________________ *The company stated relates to the precursor amine; the preparation proceeds analogously to the instructions for Examples XXXII and XXXIII.
TABLE 18__________________________________________________________________________ ##STR242##Example No. 1 R.sup.2 ##STR243## R.sub.f value (solvent) Melting Point �.degree.C.! Starting material a) Literature b) Distributing company c) Preparation analogously to Ex. No.__________________________________________________________________________203 rac cHept ##STR244## m.p. = 163-166.degree. C. b) Aldrich204 rac cHept ##STR245## R.sub.f = 0.13 (AC) b) Lancaster205 rac cHept ##STR246## R.sub.f = 0.46 (AE) b) Sigma206 rac cHept ##STR247## R.sub.f = 0.37 (AE) b) Aldrich207 rac cHept ##STR248## R.sub.f = 0.85 (AD) a) G. Bittner et al., Justus Liebigs Ann. Chem. 713, 1 (1968).208 rac cHept ##STR249## R.sub.f = 0.57 (AE) b) Aldrich209 rac cHept ##STR250## R.sub.f = 0.03 (AC) b) Aldrich210 rac cHept ##STR251## R.sub.f = 0.61 (AG) b) Columbia211 rac cHept ##STR252## R.sub.f = 0.28 (H) a) DE 2 552 196212 rac cHept ##STR253## R.sub.f = 0.62 (O) a) GB 1 129 029213 rac cHept ##STR254## R.sub.f = 0.64 (AF) c) Example No. XL__________________________________________________________________________
TABLE 19__________________________________________________________________________ ##STR255## Starting material a) Literature R.sub.f value (solvent) b) Distributing companyExample No. 1 R.sup.45 Melting point �.degree.C.! c) Preparation analogously to Ex.__________________________________________________________________________ No.214 rac CH.sub.2 CH.sub.2 OH m.p. = 91-94.degree. C. b) Aldrich215 R ##STR256## R.sub.f = 0.44 (O) b) Aldrich216 R ##STR257## R.sub.f = 0.11 (E) a) Analogously to Example 74__________________________________________________________________________
TABLE 20__________________________________________________________________________ ##STR258## R.sup.2 ##STR259## Melting point �.degree.C.! Starting material a) Literature b) Distributing company c) Preparation analogously to Ex. No.__________________________________________________________________________217 rac nBu ##STR260## m.p. = 174.degree. C. b) Aldrich218 rac nBu ##STR261## m.p. = 165-170.degree. C. c) analogously to Example No. 74 (from Example No. 219)219 rac nBu ##STR262## m.p. = 157-159.degree. C. b) Aldrich220 rac nBu CH.sub.2 COOH m.p. = 173-175.degree. C. c) analogously to Example No. 74 (from Example No. 222)221 rac nBu ##STR263## m.p. = 187.degree. C. b) Aldrich222 rac nBu CH.sub.2 CO.sub.2 Me m.p. = 177.degree. C. b) Aldrich223 -- H ##STR264## m.p. = 193.degree. C. b) Aldrich224 -- H ##STR265## m.p. = 187.degree. C. b) Aldrich__________________________________________________________________________
TABLE 21__________________________________________________________________________ ##STR266## Starting material a) Literature b) Distributing companyEx. No. (1) (2) R.sup.47 R.sub.f value (solvent) c) Preparation analogously to Ex.__________________________________________________________________________ No.225 rac rac 4-Cl R.sub.f = 0.52 (AD) c) analogously to Example No. XXXII and XXXIII (from Example No. XX)226 rac rac 3-Cl R.sub.f = 0.69 (AE) c) analogously to Example No. XXXII and XXXIII (from Example No. XIX)227 rac rac 4-Me R.sub.f = 0.67 (AE) c) analogously to Example No. XXXII and XXXIII (from Example No. XXVII)228 rac rac 2-OH R.sub.f = 0.32 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXV)229 rac rac 3-OH R.sub.f = 0.40 (B) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVI)230 rac rac 3-OSO.sub.2 Me R.sub.f = 0.49 (B) c) analogously to Example No. 90 (from Example No. 229)231 rac dia B 4-OH R.sub.f = 0.51 (C) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVII)232 rac dia A 4-OH R.sub.f = 0.60 (C) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVII)233 dia A R H R.sub.f = 0.43 (C) b) Aldrich234 dia B R H R.sub.f = 0.42 (C) b) Aldrich__________________________________________________________________________
TABLE 22__________________________________________________________________________ ##STR267## Starting material a) Literature b) Distributing companyEx. No. (1) (2) R.sup.48 R.sub.f value (solvent) c) Preparation from Example.__________________________________________________________________________ No.235 R dia A 4-cPr R.sub.f = 0.24 (V) c) III236 R dia B 4-cPr R.sub.f = 0.21 (V) c) III237 R dia A 4-tBu R.sub.f = 0.25 (V) a) WO 91 08 704238 R dia B 4-tBu R.sub.f = 0.22 (V) a) WO 91 08 704239 R rac 4-Ph R.sub.f = 0.50 (X) c) IV240 R R 4-Cl R.sub.f = 0.43 (AF) c) XXXVIII241 R S 4-Cl R.sub.f = 0.47 (X) c) XXXVIII242 R dia A 2-OH R.sub.f = 0.36 (X) c) II243 R dia B 2-OH R.sub.f = 0.28 (X) c) II244 R rac 3-OH R.sub.f = 0.35 (X) a) DE 22 04 117245 R rac 4-OH R.sub.f = 0.23 (AF) a) EP 530 879246 R rac 4-Me R.sub.f = 0.53 (X) a) F. Rose -- Munch et al., J. Organomet. Chem. 415, 223 (1991).247 R rac 4-SO.sub.2 Me R.sub.f = 0.56 (AH) c) XL248 R R 4-OH R.sub.f = 0.51 (AH) a) EP 530 879249 R rac ##STR268## R.sub.f = 0.23 (O) c) VI250 R rac ##STR269## R.sub.f = 0.22 (AF) c) XXXIX251 R dia A 3-CF.sub.3 R.sub.f = 0.25 (AF) c) XLI252 R dia B 3-CF.sub.3 R.sub.f = 0.21 (AF) c) XLI253 R dia A 4-F, 3-OPh R.sub.f = 0.26 (AF) c) XLII254 R dia B 4-F, 3-OPh R.sub.f = 0.23 (AF) c) XLII255 R S H R.sub.f = 0.55 (X) b) Aldrich256 S S H R.sub.f = 0.53 (X) b) Aldrich257 R dia A 4-OCF.sub.3 R.sub.f = 0.33 (Af) c) XLIII258 R dia B 4-OCF.sub.3 R.sub.f = 0.28 (AF) c) XLIII259 R R H R.sub.f = 0.50 (X) b) Aldrich260 R rac 3,4-(OH).sub.2 R.sub.f = 0.29 (A) c) XLIV__________________________________________________________________________
TABLE 23__________________________________________________________________________ ##STR270## Example No. 2 ##STR271## R.sub.f value (solvent) Starting material a) Literature b) Distributing company c) Preparation from Example No.__________________________________________________________________________261 R rac ##STR272## R.sub.f = 0.31 (AE) c) IX262 R rac ##STR273## R.sub.f = 0.66 (X) C) V263 R rac ##STR274## R.sub.f = 0.43 (X) a) G. H. Hakimelahi and G. Just, Can. J. Chem. 57, 1932 (1979).264 S rac ##STR275## R.sub.f = 0.38 (X) a) DE 22 04 117265 R rac ##STR276## R.sub.f = 0.26 (AF) a) DE 22 04 117266 S S ##STR277## R.sub.f = 0.34 (D) b) Aldrich__________________________________________________________________________
TABLE 24__________________________________________________________________________ ##STR278## Starting material a) Literature b) Distributing company c) Preparation analogously to Example.Ex. No. (1) (2) R.sup.50 R.sub.f value (solvent) No.__________________________________________________________________________267 R R 4-Cl R.sub.f = 0.35 (O) c) analogously to Example No. 21 (from Example No. 240)268 R rac 4-Ph R.sub.f = 0.22 (O) c) analogously to Example No. 21 (from Example No. 239)269 R S 4-Cl R.sub.f = 0.33 (O) c) analogously to Example No. 21 (from Example No. 241)270 R dia B 2-OH R.sub.f = 0.28 (AH) c) analogously to Example No. 21 (from Example No. 243)271 R dia A 2-OH R.sub.f = 0.29 (AH) c) analogously to Example No. 21 (from Example No. 242)272 R dia B 4-cPr R.sub.f = 0.26 (O) c) analogously to Example No. 21 (from Example No. 236)273 R dia A 4-cPr R.sub.f = 0.26 (O) c) analogously to Example No. 21 (from Example No. 235)274 R rac 4-OH R.sub.f = 0.24 (AE) c) analogously to Example No. 21 (from Example No. 245)275 R dia A 4-tBu R.sub.f = 0.35 (O) c) analogously to Example No. 21 (from Example No. 237)276 R dia B 4-tBu R.sub.f = 0.32 (O) c) analogously to Example No. 21 (from Example No. 238)277 R R 4-OH R.sub.f = 0.46 (AI) c) analogously to Example No. 21 (from Example No. 248)278 R rac 4-SO.sub.2 Me R.sub.f = 0.31 (AI) c) analogously to Example No. 21 (from Example No. 247)279 R rac ##STR279## R.sub.f = 0.33 (O) c) analogously to Example No. 21 (from Example No. 250)280 S Dia B 2-OH R.sub.f = 0.50 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXV)281 S S 4-Cl R.sub.f = 0.21 (O) c) analogously to Example No. XXXII and XXXIII282 S dia A 2-OH R.sub.f = 0.37 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXV)283 R dia A 2-OH, 3-I R.sub.f = 0.30 (O) c) analogously to Example No. XXXII and XXXIII284 R dia B 2-OH, 3-I R.sub.f = 0.29 (O) c) analogously to Example No. XXXII and XXXIII285 S R 4-Cl R.sub.f = 0.23 (O) c) analogously to Example No. XXXII and XXXIII286 S rac 4-F R.sub.f = 0.34 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XVIII)287 S rac 3-OH R.sub.f = 0.25 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVI)288 S rac 2-F R.sub.f = 0.37 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XVII)289 R rac 2-F R.sub.f = 0.39 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XVII)290 R rac ##STR280## R.sub.f = 0.13 (AE) c) analogously to Example No. 21 (from Example No. 249)291 R dia B 3-CF.sub.3 R.sub.f = 0.39 (O) c) analogously to Example No. 21 (from Example 251)292 R dia A 3-CF.sub.3 R.sub.f = 0.28 (O) c) analogously to Example No. 21 (from Example No. 251)293 R dia A 4-OCF.sub.3 R.sub.f = 0.13 (X) c) analogously to Example No. 21 (from Example No. 257)294 R dia B 4-OCF.sub.3 R.sub.f = 0.29 (O) c) analogously to Example No. 21 (from Example No. 258)295 R dia B 4-F, 2-OPh R.sub.f = 0.13 (O) c) analogously to Example No. 21 (from Example No. 254)296 R dia A 4-F, 3-OPh R.sub.f = 0.22 (O) c) analogously to Example No. 21 (from Example No. 253)297 R rac 3-OH R.sub.f = 0.26 (AE) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVI)298 R rac 4-Me R.sub.f = 0.53 (O) c) analogously to Example No. 21 (from Example No. 246)299 R rac 4-CH.sub.2 OH R.sub.f = 0.27 (AE) c) analogously to Example No. XXXII and XXXIII__________________________________________________________________________
TABLE 25__________________________________________________________________________ ##STR281##Example No. 1 2 ##STR282## R.sub.f value (solvent) Starting material Preparation from Example__________________________________________________________________________ No.300 R rac ##STR283## R.sub.f = 0.20 (O) 262301 R rac ##STR284## R.sub.f = 0.32 (AH) 263302 R rac ##STR285## R.sub.f = 0.06 (W) 261303 R S ##STR286## R.sub.f = 0.40 (O) 265304 S rac ##STR287## R.sub.f = 0.28/0.38 (O) 264305 S S ##STR288## R.sub.f = 0.36 (O) 264306 R R ##STR289## R.sub.f = 0.32 (O) 265__________________________________________________________________________
TABLE 26__________________________________________________________________________ ##STR290## Starting material a) Literature R.sub.f value (solvent) b) Distributing companyEx. No. (1) (2) R.sup.52 Melting point �.degree.C.! c) Preparation analogously to Ex.__________________________________________________________________________ No.307 R dia A ##STR291## R.sub.f = 0.26 (O) c) analogously to Example No. XXXII and XXXIII308 R dia B ##STR292## R.sub.f = 0.21 (O) c) analogously to Example No. XXXII and XXXIII309 R dia A 4-OCF.sub.3 R.sub.f = 0.33 (O) c) analogously to Example No. XXXII and XXXIII310 R dia B 4-OCF.sub.3 R.sub.f = 0.26 (O) c) analogously to Example No. XXXII and XXXIII311 R dia A 2-OH R.sub.f = 0.39 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXV)312 R dia B 2-OH R.sub.f = 0.26 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXV)313 R S 4-Cl R.sub.f = 0.32 (O) c) analogously to Example No. 21314 R dia A 4-Ph R.sub.f = 0.40 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. IV)315 R dia B 4-Ph R.sub.f = 0.35 (O) c) analogously to Example No. XXXII and XXXIII (from Example No. IV)316 R dia A ##STR293## R.sub.f = 0.09 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. VI)317 R dia B ##STR294## R.sub.f = 0.09 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. VI)318 R dia A 3-CF.sub.3 R.sub.f = 0.48 (O) c) analogously to Example No. XXXII and XXXIII319 R rac 3-OH R.sub.f = 0.21 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVI)320 R dia B 3-CF.sub.3 R.sub.f = 0.41 (O) c) analogously to Example No. XXXII and XXXIII321 R rac 4-OH R.sub.f = 0.21 (AH) c) analogously to Example No. XXXII and XXXIII (from Example No. XXXVII)__________________________________________________________________________
TABLE 27__________________________________________________________________________ ##STR295## Starting materialExample No. 1 2 R.sup.53 R.sub.f value (solvent) Preparation from Example No.__________________________________________________________________________322 R dia B ##STR296## R.sub.f = 0.36 (O) V323 R dia A ##STR297## R.sub.f = 0.40 (O) V__________________________________________________________________________
TABLE 28__________________________________________________________________________ ##STR298## Starting materialExample No. 1 2 R.sup.54 R.sub.f value (solvent) Preparation from Example No.__________________________________________________________________________324 R dia A 3-CF.sub.3 R.sub.f = 0.02 (AH) 251325 R dia B 3-CF.sub.3 R.sub.f = 0.02 (AH) 252326 R dia A 4-OCF.sub.3 R.sub.f = 0.02 (AH) 257327 R dia B 4-OCF.sub.3 R.sub.f = 0.02 (AH) 258328 R dia B 4-F, 3-OPh R.sub.f = 0.02 (AH) 254329 R S H R.sub.f = 0.01 (AH 255330 R R H R.sub.f = 0.01 (AH) 259331 S S H R.sub.f = 0.01 (AH) 256332 R dia A 4-F, 3-OPh R.sub.f = 0.02 (AH) 253__________________________________________________________________________
TABLE 29__________________________________________________________________________ ##STR299## Starting materialExample No. 1 2 R.sup.55 R.sub.f value (solvent) Preparation from Example No.__________________________________________________________________________333 R rac ##STR300## R.sub.f = 0.69 (AJ) 262334 R rac ##STR301## R.sub.f = 0.55 (AE) 261335 rac rac ##STR302## R.sub.f = 0.31 (C) 263336 S rac ##STR303## R.sub.f = 0.56 (C) 264337 R rac ##STR304## R.sub.f = 0.53 (C) 265__________________________________________________________________________
TABLE 30______________________________________ ##STR305##Example No. 1 2 R.sup.1 R.sup.2 R.sub.f value (solvent)______________________________________338 rac S OH cHex R.sub.f = 0.52 (AE)339 R S H cPent R.sub.f = 0.61 (AJ)340 S S H cPent R.sub.f = 0.48 (AJ)341 R R H cPent R.sub.f = 0.38 (Z)342 rac rac OH ##STR306## R.sub.f = 0.48 (AE)343 rac rac H cDodec R.sub.f 0.34 (F)344 rac rac H cOct R.sub.f = 0.30 (F)______________________________________ D,L-Phenylglycincamide is commercially obtainable from Bader.
TABLE 31__________________________________________________________________________ ##STR307## Starting materialExample No. (1) (2) R.sup.56 R.sub.f value (solvent) Preparation from Example__________________________________________________________________________ No.345 R rac 4-Cl R.sub.f = 0.47 (AD) 240346 R S 4-Cl R.sub.f = 0.48 (AE) 241347 S S 4-Cl R.sub.f = 0.61 (AJ) 240/241348 S R 4-Cl R.sub.f = 0.45 (AD) 240/241349 R rac 4-OCF.sub.3 R.sub.f = 0.35 (Z) 257350 R rac 4-Ph R.sub.f = 0.51 (AJ) 239351 R rac 4-cPr R.sub.f = 0.48 (AJ) 235352 R rac 4-cPr R.sub.f = 0.47 (AJ) 236353 R rac 4-tBu R.sub.f = 0.55/0.50 (Z) 237/238354 R rac 4-OCF.sub.3 R.sub.f = 0.28 (AJ) 258355 R rac ##STR308## R.sub.f = 0.33 (AE) 249356 rac rac 2-OH R.sub.f = 0.38 (AG) 242/243357 rac rac 4-OH R.sub.f = 0.30 (C) 245358 rac dia A 4-OH R.sub.f = 0.27 (C) 245359 rac rac 3-OH R.sub.f = 0.31 (C) 244360 rac rac 4-F, 3-OPh R.sub.f = 0.52 (C) 253/254361 rac rac 4-SO.sub.2 Ph R.sub.f = 0.47 (C) 247362 R rac 3-CF.sub.3 R.sub.f = 0.33 (F) 251/252__________________________________________________________________________
TABLE 32__________________________________________________________________________ ##STR309## Starting materialExample No. (1) (2) R.sup.1 R.sup.57 R.sub.f value (solvent) Preparation from Example__________________________________________________________________________ No.363 rac dia A H H R.sub.f = 0.19 (O) analogously to Example No. XXXII and XXXIII*364 rac dia B H H R.sub.f = 0.19 (O) analogously to Example No. XXXII and XXXIII*365 R rac H ##STR310## R.sub.f = 0.30 (Z) analogously to Example No. 76366 rac dia A OH H R.sub.f = 0.16 (O) analogously to Example No. XXXII and XXXIII*367 rac dia B OH H R.sub.f = 0.16 (O) analogously to Example No. XXXII and XXXIII*368 rac rac H 2-OH R.sub.f = 0.14 (O) analogously to Example No. 76369 rac rac H 3-OH R.sub.f = 0.30 (AG) analogously to Example No. 76370 rac rac H ##STR311## R.sub.f = 0.28 (O) analogously to Example No. 76371 rac dia A H ##STR312## R.sub.f = 0.28 (O) analogously to Example No. 76372 R dia A H H R.sub.f = 0.17 (O) analogously to Example No. XXXII and XXXIII*373 R dia B H H R.sub.f = 0.17 (O) analogously to Example No. XXXII and XXXIII*374 S dia A H H R.sub.f = 0.26 (O) analogously to Example No. XXXII and XXXIII*375 S dia B H H R.sub.f = 0.26 (O) analogously to Example No. XXXII and XXXIII*__________________________________________________________________________ *D,L-Phenylglycineamide is commercially obtainable from Bader.
TABLE 33__________________________________________________________________________ ##STR313##Example No. 1 2 A D R.sup.1 R.sub.f value (solvent)__________________________________________________________________________376 rac rac H CH.sub.2CH.sub.2 H R.sub.f = 0.56 (AE)377 rac rac H iBu H R.sub.f = 0.67/061 (AE)378 rac rac iBu H H R.sub.f = 0.35 (F)379 rac rac ##STR314## H H R.sub.f = 0.33 (F)380 rac rac OMe H OH R.sub.f = 0.28 (F)381 rac rac iBu H OH R.sub.f = 0.30 (F)382 rac rac F H H R.sub.f = 0.30 (F)__________________________________________________________________________ D,L-Phenylglycinamide is commercially obtainable from Bader.
TABLE 34__________________________________________________________________________ ##STR315## Starting material a) Literature b) Distributing company R.sub.f value (solvent) c) Synthesis anologously to/fromExample 1 R.sup.59 Melting point �.degree.C.! Example No.__________________________________________________________________________383 S ##STR316## R.sub.f = 0.49 (AK) b) Aldrich384 R ##STR317## m.p = 109.degree. C. b) Aldrich385 S ##STR318## R.sub.f = 0.49 (AK) b) Aldrich386 S ##STR319## R = 0.48 (AK) b) Aldrich387 S ##STR320## m.p. = 173.degree. C. b) Aldrich388 R ##STR321## m.p. = 161.degree. C. b) Aldrich389 R ##STR322## R.sub.f = 0.43 (AL) a) F. Zymalkowski Arch. Pharm. 291, 12 (1958).390 S ##STR323## R.sub.f = 0.42 (AL) a) F. Zymalkowski Arch. Pharm. 291, 12 (1958).391 R ##STR324## R.sub.f = 0.39 (B) b) K & K392 S ##STR325## R.sub.f = 0.39 (B) b) K & K393 S ##STR326## m.p. = 118.degree. C. b) K & K394 R ##STR327## m.p. = 120.degree. C. b) K & K395 S ##STR328## R.sub.f = 0.53 (AK) a) J. Millen et al., J. Med. Chem. 28, 12 (1985).396 R ##STR329## R.sub.f = 0.53 (AK) a) J. Millen et al., J. Med. Chem. 28, 12 (1985).397 S ##STR330## R.sub.f = 0.58 (AK) a) D. P. Davis et al., J. Med. Chem. 24, 12 (1981)398 R ##STR331## R.sub.f = 0.57 (AK) a) D. P. Davis et al., J. Med. Chem. 24, 12 (1981)399 S ##STR332## R.sub.f = 0.60 (AK) a) EP 518 672400 R ##STR333## R.sub.f = 0.60 (AK) a) EP 518 672__________________________________________________________________________

Claims

1. 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives of the general formula ##STR334## in which A and D are identical or different and represent hydrogen, cycloalkyl having 3 to 8 carbon atoms, azido, hydroxyl, halogen, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 6 carbon atoms, or a 5- to 6- membered unsaturated or saturated heterocyclic radical having up to 3 heteroatoms from the series consisting of S, N and/or O,
R.sup.1 represents hydrogen or hydroxyl, or represents straight-chain or branched alkyl having up to 4 carbon atoms,
R.sup.2 represents hydrogen, hydroxyl, halogen, straight-chain or branched alkenyl or alkoxy having in each case up to 8 carbon atoms or cycloalkyl having 3 to 14 carbon atoms, or represents straight-chain or branched alkyl having up to 8 carbon atoms, which is optionally substituted by cycloalkyl having 3 to 14 carbon atoms, phenyl or tetrahydropyranyl, which in their turn can be substituted by halogen, or represents the indanyl radical,
or
R.sup.1 and R.sup.2 together with the carbon atom form a saturated carbocyclic ring having 5 to 7 carbon atoms,
or
R.sup.1 and R.sup.2 together represent a double bond radical of the formula ##STR335## wherein a denotes the number 2, 3, 4, 5, or 6,
E represents a radical of the formula ##STR336## in which R.sup.3 denotes phenyl, methyl or a typical amino-protective group,
R.sup.4 and R.sup.4 are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen,
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 4 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which is optionally substituted up to twice in an identical or different manner by halogen, hydroxyl, pyrrolidinyl, morpholino, amino, trifluoromethyl, trifluoromethoxy, cycloalkyl having 3 to 6 carbon atoms or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl, or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by halogen or by straight-chain or branched alkyl having up to 4 carbon atoms, and/or are optionally substituted by a group of the formula --(O).sub.c --SO.sub.2 R.sup.12,
wherein
c denotes the number 0 or 1 and
R.sup.12 denotes straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
b denotes the number 0, 1 or 2,
T denotes a 5 to 7-membered, optionally benzo-fused, saturated, partially unsaturated or unsaturated heterocyclic radical having up to 3 heteroatoms from the series consisting of S, N and/or O, wherein both rings are optionally substituted up to three times in an identical or different manner by halogen, hydroxyl, morpholino, amino, cycloalkyl having 3 to 6 carbon atoms, straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms or phenyl,
V has the abovementioned meaning of L or T or denotes a radical of the formula ##STR337## wherein d denotes the number 1, 2 or 3,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.e --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
R.sup.7 denotes hydrogen, cyano, trifluoromethyl or straight-chain or branched alkenyl or alkyl having up to 7 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 4 carbon atoms, or denotes alkoxy having up to 6 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15,
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and
denote hydrogen, phenyl or straight-chain or branched alkyl having up to 4 carbon atoms,
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 4 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cycloalkyl having 3 to 6 carbon atoms or phenyl, or
denote straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by phenyl, cycloalkyl having 3 to 6 carbon atoms, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 4 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17 wherein
R.sup.16 and R.sup.17 are identical or different and denote hydrogen, phenyl
or straight-chain or branched alkyl having up to 4 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR338## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, a typical amino-protective group or a radical of the formula --SO.sub.2 R.sup.19.
wherein
R.sup.19 denotes straight-chain or branched alkyl having up to 4 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branched alkyl having 2 to 7 carbon atoms, which is substituted one to three times in an identical or different manner by hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy,
or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 6 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen and
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 4 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 4 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR339## or phenyl which is optionally substituted up to twice in an identical or different manner by halogen, carboxyl or straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, halogen or by straight-chain or branched alkoxycarbonyl having up to 5 carbon atoms,
and salts thereof, wherein
2-�4-(quinolin-2-yl-methoxy)-phenyl!-2-cyclopentylacetic acid �(L)-2-hydroxy-1-phenylethyl!amide
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid methyloxycarbonylmethylamide,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptylacetamide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide are excluded.
2. 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives according to claim 1,
wherein
A and D are identical or different and
represent hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, azido, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 5 carbon atoms, pyrryl or imidazolyl,
R.sup.1 represents hydrogen or hydroxyl or represents straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.2 represents hydrogen, hydroxy, fluorine, chlorine, bromine, straight-chain or branched alkenyl or alkoxy having in each case up to 7 carbon atoms, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl or cyclododecyl, or
represents straight-chain or branched alkyl having up to 7 carbon atoms, which is optionally substituted by cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl or cyclododecyl, phenyl or tetrahydropyranyl, which in their turn can be substituted by fluorine, chlorine or bromine, or
represents the indanyl radical,
or
R.sup.1 and R.sup.2 together with the carbon atom form a cyclopentyl, cyclohexyl or cycloheptyl ring,
or
R.sup.1 and R.sup.2 together represent a double bond radical of the formula ##STR340## wherein a denotes the number 2, 3, 4 or 5,
E represents a radical of the formula ##STR341## in which R.sup.3 denotes phenyl, methyl, acetyl or tert-butoxycarbonyl (Boc),
R.sup.4 and R.sup.4' are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen,
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 3 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which are optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, iodine, hydroxyl, pyrrolidinyl, morpholino, amino, trifluoromethyl, trifluoromethoxy, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by fluorine, chlorine, bromine or by straight-chain or branched alkyl having up to 3 carbon atoms,
and/or are optionally substituted by a group of the formula --(O).sub.c SO.sub.2 --R.sup.12,
wherein
c denotes the number 0 or 1,
and
R.sup.12 denotes straight-chain or branched alkyl having up to 4 carbon atoms or phenyl,
b denotes the number 0 or 1,
T denotes a heterocyclic radical of the formula ##STR342## wherein R.sup.25 and R.sup.26 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or amino,
V has the abovementioned meaning of L or T or denotes a radical of the formula ##STR343## wherein denotes the number 1 or 2,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.d --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
R.sup.7 denotes hydrogen, cyano, trifluoromethyl, vinyl or straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 3 carbon atoms, or denotes alkoxy having up to 5 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and
denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 3 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cyclopropyl, cyclopentyl, cyclohexyl or phenyl, or
denote straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by phenyl, cyclopropyl, cyclopentyl, cyclohexyl, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 3 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17,
wherein
R.sup.16 and R.sup.17 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR344## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, tert-butoxycarbonyl or a radical of the formula --SO.sub.2 R.sup.19,
wherein
R.sup.19 denotes straight-chain or branched alkyl having up to 3 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branch alkyl having 2 to 7 carbon atoms, which is substituted 1 to 3 times in an identical or different manner by hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy, or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 5 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen,
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 3 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 3 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR345## phenyl, which is optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, carboxyl or straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, fluorine, chlorine, bromine or by straight-chain or branched alkoxycarbonyl having up to 4 carbon atoms,
and salts thereof, wherein
2-�4-(quinolin-2-yl-methoxy)-phenyl!-2-cyclopentylacetic acid �(L)-2-hydroxy-1-phenylethyl!amide
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid methyloxycarbonylmethylamide,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptylacetamide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide are excluded.
3. 4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives according to claim 1,
wherein
A and D are identical or different and
represent hydrogen, cyclopropyl, cyclopentyl, cyclohexyl, azido, hydroxyl, fluorine, chlorine, bromine, straight-chain or branched alkyl, alkoxy or alkenyl having in each case up to 4 carbon atoms, imidazolyl or pyrryl,
R.sup.1 represents hydrogen, hydroxyl or straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.2 represents hydrogen, hydroxyl, fluorine, chlorine, straight-chain or branched alkenyl or alkoxy having in each case up to 5 carbon atoms, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl or cycloundecyl or
represents straight-chain or branched alkyl having up to 6 carbon atoms, which is optionally substituted by cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cycloundecyl, phenyl or tetrahydropyranyl, which in their turn can be substituted by fluorine, chlorine or bromine,
or
represents the indanyl radical,
R.sup.1 and R.sup.2 together with the carbon atom form a cyclopentyl, cyclohexyl or cycloheptyl ring,
E represents a radical of the formula ##STR346## in which R.sup.3 denotes phenyl, methyl, acetyl or tert-butoxycarbonyl (Boc),
R.sup.4 and R.sup.4' are identical or different and have the abovementioned meaning of R.sup.3 or denote hydrogen,
R.sup.5 denotes straight-chain or branched acyl or alkyl having in each case up to 3 carbon atoms,
L denotes phenyl, benzyl or naphthyl, which are optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, iodine, hydroxyl, pyrrolidinyl, morpholino, trifluoromethoxy, trifluoromethyl, amino, cyclopropyl, cyclopentyl, cyclohexyl or straight-chain or branched alkyl or alkoxy having in each case up to 6 carbon atoms, which in their turn can be substituted by hydroxyl, or are optionally substituted by phenyl or phenoxy, which in their turn can be substituted up to twice in an identical or different manner by fluorine, chlorine or by straight-chain or branched alkyl having up to 3 carbon atoms,
and/or are optionally substituted by a group of the formula --(O).sub.c SO.sub.2 --R.sup.12,
wherein
denotes the number 0 or 1,
and
R.sup.12 denotes straight-chain or branched alkyl having up to 3 carbon atoms or phenyl,
b denotes the number 0 or 1,
T denotes a heterocyclic radical of the formula ##STR347## wherein R.sup.25 and R.sup.26 are identical or different and denote hydrogen, straight-chain or branched alkyl having up to 4 carbon atoms or amino,
V has the abovementioned meaning of L or T or
denotes a radical of the formula ##STR348## wherein d denotes the number 1 or 2,
R.sup.6 denotes a radical of the formula --(CH.sub.2).sub.d --R.sup.13,
wherein
e denotes the number 0 or 1,
R.sup.13 denotes hydroxyl, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
wherein
R.sup.7 denotes hydrogen, cyano, trifluoromethyl, vinyl or straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by straight-chain or branched alkoxy having up to 3 carbon atoms, or denotes alkoxy having up to 3 carbon atoms, or denotes a group of the formula --CO--NH--(CH.sub.2).sub.f --NR.sup.14 R.sup.15,
wherein
f denotes the number 1, 2 or 3,
R.sup.14 and R.sup.15 are identical or different and
denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
R.sup.8 denotes hydrogen, carboxyl, straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms or straight-chain or branched alkyl having up to 4 carbon atoms, which is optionally substituted by hydroxyl, carboxyl or by straight-chain or branched alkoxycarbonyl having in each case up to 3 carbon atoms or phenyl,
R.sup.9 and R.sup.10 are identical or different and
denote hydrogen, cyclopropyl, cyclopentyl, cyclohexyl or phenyl, or
denote straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted by phenyl, cyclopropyl, cyclopentyl, cyclohexyl, hydroxyl, carboxyl, by straight-chain or branched alkoxy or alkoxycarbonyl having in each case up to 3 carbon atoms or by a group of the formula --NR.sup.16 R.sup.17,
wherein
R.sup.16 and R.sup.17 are identical or different and denote hydrogen, phenyl or straight-chain or branched alkyl having up to 3 carbon atoms,
or
R.sup.9 and R.sup.10 together with the nitrogen atom form a heterocyclic radical of the formula ##STR349## wherein Z denotes an oxygen atom or the group --NR.sup.18 or --CH,
wherein
R.sup.18 denotes hydrogen, acetyl, tert-butoxycarbonyl or a radical of the formula --SO.sub.2 R.sup.19,
wherein
R.sup.19 denotes straight-chain or branched alkyl having up to 3 carbon atoms, benzyl or phenyl, which is optionally substituted by phenyl or tolyl,
W denotes straight-chain or branched alkyl having 2 to 7 carbon atoms, which is substituted 1 to 3 times in an identical or different manner by hydroxyl, pyridyl, norbornyl or phenyl, which in its turn can be substituted by hydroxyl or benzyloxy, or is substituted by a group of the formula --OR.sup.20 or --NR.sup.21 R.sup.22,
wherein
R.sup.20 denotes straight-chain or branched alkyl having up to 4 carbon atoms and
R.sup.21 and R.sup.22 are identical or different and have the abovementioned meaning of R.sup.16 and R.sup.17,
X denotes an oxygen or sulphur atom,
Y denotes formyl or the group --CHR.sup.23 R.sup.24,
wherein
R.sup.23 denotes hydrogen,
R.sup.24 denotes hydroxyl or straight-chain or branched alkoxy or acyl having in each case up to 3 carbon atoms,
or
R.sup.23 and R.sup.24 are identical or different and denote straight-chain or branched alkoxy having up to 3 carbon atoms,
R.sup.11 denotes a radical of the formula ##STR350## or phenyl, which is optionally substituted up to twice in an identical or different manner by fluorine, chlorine, bromine, carboxyl or straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
or
denotes straight-chain or branched alkyl having up to 5 carbon atoms, which is optionally substituted up to twice in an identical or different manner by hydroxyl, carboxyl, fluorine, chlorine, bromine or by straight-chain or branched alkoxycarbonyl having up to 3 carbon atoms,
and salts thereof, wherein
2-�4-(quinolin-2-yl-methoxy)-phenyl!-2-cyclopentylacetic acid �(L)-2-hydroxy-1-phenylethyl!amide
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid methyloxycarbonylmethylamide,
2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid carboxymethylamide,
N-methyl-2-�3-isobutyl-4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-methyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid amide,
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetic acid amide and
N-ethyl-2-�4-(quinolin-2-yl-methoxy)phenyl!-2-cyclohexyl-acetic acid amide are excluded.
4. A compound according to claim 1 wherein such compound is (2S)-2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cyclopentyl-acetic acid (R)-(O-acetyl)-phenylglycinolamide of the formula ##STR351## and a salt thereof.
5. A compound according to claim 1 wherein such compound is 2-{4-�Quinolin-2-yl-methoxy!phenyl}-2-cyclopentyl acetic acid �4-tert-butylphenyl!glycinol-amide of the formula ##STR352## and a salt thereof.
6. A compound according to claim 1 wherein such compound is 2-�4-(Quinolin-2-yl-methoxy)phenyl!-2-cycloheptyl-acetic acid (phenylglycine ethyl ester)-amide of the formula ##STR353## and a salt thereof.
7. A compound according to claim 1 wherein such compound is (2S)-2-�4-(Quinolin-2-yl-methoxy)-phenyl!-2-cycloheptyl-acetic acid N-(1-phenyl-vinyl)amide of the formula ##STR354## and a salt thereof.
8. A compound according to claim 1 wherein such compound is (.alpha.-Hydroxymethyl)benzyl 2-�4-quinolin-2-yl-methoxy)phenyl!-2-cyclopentyl-acetate of the formula ##STR355## and a salt thereof.
9. A composition for the treatment of atherosclerosis comprising an amount effective therefor of a compound or salt thereof according to claim 1 and a pharmacologically acceptable diluent.
10. A method of treating atherosclerosis in a patient in need thereof which comprises a compound or a salt thereof according to claim 1.

Priority Claims (1)

Number	Date	Country	Kind
44 43 892.3	Dec 1994	DEX

US Referenced Citations (21)

Number	Name	Date
3880919	Oediger et al.	Apr 1975
3915992	Baxter-Smallwood et al.	Oct 1975
3976680	Clark et al.	Aug 1976
3988448	Bowman	Oct 1976
4088815	Breuer et al.	May 1978
4138397	Bohme	Feb 1979
4216329	Secor	Aug 1980
4474780	Daugherty	Oct 1984
4734407	Schmidt et al.	Mar 1988
4748163	Schmidt et al.	May 1988
4929626	Mohrs et al.	May 1990
4970215	Mohrs et al.	Nov 1990
5091392	Raddatz et al.	Feb 1992
5126354	Mohrs et al.	Jun 1992
5254682	Dhanoa et al.	Oct 1993
5292769	Mohrs et al.	Mar 1994
5306820	Decker et al.	Apr 1994
5336805	Boesten et al.	Aug 1994
5422342	Henke et al.	Jun 1995
5432173	Husson et al.	Jul 1995
5466699	Robertson et al.	Nov 1995

Foreign Referenced Citations (21)

Number	Date	Country
0344519	Dec 1989	EPX
0399291	Nov 1990	EPX
0414076	Feb 1991	EPX
0499926	Aug 1992	EPX
0514267	Nov 1992	EPX
0518672	Dec 1992	EPX
0529450	Mar 1993	EPX
0530639	Mar 1993	EPX
0545170	Jun 1993	EPX
0545171	Jun 1993	EPX
0549879	Jul 1993	EPX
0574774	Dec 1993	EPX
0582916	Feb 1994	EPX
0582908	Feb 1994	EPX
2162717	Jun 1973	DEX
2836613	Mar 1980	DEX
3900261	Dec 1989	DEX
1129029	Mar 1967	GBX
1434826	May 1976	GBX
9118897	Dec 1991	WOX
9410148	May 1994	WOX

Non-Patent Literature Citations (29)

Entry
R. Ross, J. Cell. Biol., vol. 50, pp. 172-186 (1971).
P. Mertes, et al., J. Med. Chem., vol. 12, pp. 342-343, 1969.
R. Williams, J. Org. Chem, vol. 55, pp. 3723-3728, (1990).
G. Schmidt, et al., in "Recent Advances in Chem. therapy", ed. D. Adams, et al. , pp 2428-2429, Futruamed Publishers, Munich, Germany, (1992).
M. Hatanaka, et al. , J. Med. Chem., vol. 16, No. 9, pp 978-984 (1973).
E. Compere, Jr., et al., Synthesis, pp 852-853 (1977).
J. Knabe, et al., Arch. Pharm., vol. 306, pp. 648-658, (1973).
Y. Oka, et al., Chem. Pharm. Bull., vol 18, No. 3, pp 527-533 (1970).
A. Sonn, et al. Chem. Ber., vol. 66, pp 1900-1903, (1933).
F. Rose-Munch, J. Organomet. Chem., vol. 415, pp 223-255, (1991)
G. Hakimelaki, et al., Can. J. Chem., vol. 57, pp 1932-1938, (1979).
Z. Jedlinski, et al., J. Org. Chem., vol. 52, pp 4601-4602, (1987).
S.J. Daum, et al., Syn. Commun., vol. 11, pp. 1-5, (1981).
H. Boungarten, J. Org. Chem, vol. 31, pp. 3708-3711, (1966).
E. Niemers, et al., Synthesis, pp. 593-595 (1976).
T.P. Sycheva, Chem. Heterocycl. Compounds, pp. 526-531, (1966).
V.M. Aryuzina, et al., Chem. Heterocycl. Compounds, pp 460-464, (1966).
S. Rida, et al., Pharmazie, vol. 41, pp.563-565, (1986).
C. Barney, Tetrahedron Lett., vol. 31, pp. 5547-5550, (1990).
H.V. Secor, J. Org. Chem., vol. 43, No. 12, pp. 2539-2541, (1978).
A.D. Bolat, Khim Farm. Zh., vol. 25, p. 60, (1991).
A.I. Meyers, J. Org. Chem., vol. 43, No. 5, pp 892-898, (1978).
B. Rossiter, et al., Tetrahedron, vol. 49, No. 5, pp. 965-986, (1993).
J. Brittain, et al., Tetrahedron Lett., vol. 34, No. 21, pp. 3363-3366.
G. Bittner, et al., Ann. Chem., vol. 713, pp. 1-11, (1968).
P. Tinapp., Arch. Pharm., vol. 310, pp. 89-94, (1993).
F. Zymalkowski, Arch. Pharm., vol. 291, pp.12-22, (1958).
J. Millen, J. Med. Chem., vol. 28, pp. 12-17, (1985).
D.P. Davis, J. Med. Chem., vol. 24, pp. 12-16, (1981).

4-(Quinolin-2-yl-methoxy)-phenyl-acetic acid derivatives

Information

Patent Number

Date Filed

Date Issued

Inventors

Original Assignees

Examiners

Agents

CPC

US Classifications

Field of Search

US